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CHAPTER 1 
 INTRODUCTION 
GPI TRANSAMIDASE AND GPI ANCHORED PROTEINS: ONCOGENES AND 
BIOMARKERS FOR CANCER 
 
Most of this chapter was published in an invited review: Gamage, D. G. and 
Hendrickson, T. L. “GPI transamidase and GPI anchored proteins: oncogenes 
and biomarkers for cancer.” 2013, Crit. Rev. Biochem. Mol Biol. 48(5): 446-464 
 
1.1 Introduction 
Cancer is caused by uncontrolled abnormal cell growth. According to 
statistics from the American Cancer Society, in the United States nearly one in 
two men and one in three women will develop a cancer in his or her lifetime. 
Cancer is also a public health threat worldwide. Geographic variations in cancer 
types and prevalence can arise from differences in regional lifestyle, genetics, 
diet and pollution, amongst other factors.1 
In addition to the emotional toll of cancer on patients, family, and friends, 
statistics from the American Cancer Society illustrate the devastating economic 
impact of cancer worldwide, which stem from direct costs for medical care and 
rehabilitation and indirect costs from morbidity and mortality.1 In order to reduce 
cancer mortality and improve each patient’s quality of life, it is important to 
understand how different oncogenes and biomarkers participate in cancer onset, 
progression, and metastasis. Several well established cancer biomarkers, 
including the urokinase plasminogen-activated receptor (uPAR) and the folate 
2	  
	  
	  
	  
receptor, are C-terminally modified with a glycosylphosphatidylinositol (GPI) 
anchor.2,3 This glycolipid anchor is clearly essential for proper translocation of 
these proteins; however, evidence supporting any further functional involvement 
for the GPI anchor, particularly with respect to tumor phenotypes, was minimal. 
In 2004, the discovery of the GPI anchor biosynthesis class U protein (PIG-U) as 
an oncogene in human bladder cancer opened a new door to the possibility that 
the enzyme involved in GPI anchoring, called GPI transamidase or GPI-T, might 
itself be tumorigenic.4 PIG-U is one of the five subunits that comprise the human 
GPI-T although the function of PIG-U in this enzyme is unknown.5 The reaction 
catalyzed by GPI-T and the chemical structure of a typical human GPI anchor are 
shown in Figure 1.1. 
GPI membrane anchoring of proteins is an abundant phenomenon that 
specifically tethers proteins to lipid bilayers. Approximately 0.5% of all eukaryotic 
proteins are modified or predicted to be modified by GPI-T to contain a GPI 
anchor.6 GPI anchored proteins are almost exclusively localized on the cell 
surface where they are non-covalently associated with the plasma membrane via 
the lipid portion of the anchor. GPI anchored proteins are engaged in diverse 
processes like immune recognition, cellular communication, signal transduction, 
and embryogenesis.7,8,9,10,11 Loss of GPI anchoring is embryonically lethal to 
mammals and conditionally lethal to yeast.10, 12,13 Defects in GPI anchor 
biosynthesis can cause diseases like paroxysmal nocturnal hemoglobinuria and 
hyperphosphatasia mental retardation syndrome and a mutation in the PIG-T  
3	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Figure 1.1: The chemical structure of the GPI anchor and the reaction 
catalyzed by GPI-T. (a) Left: The basic chemical structure of a human GPI 
anchor from nucleated cells is shown as a representative example. Right: A 
simplified cartoon representation of this GPI anchor.  (b) The reaction catalyzed 
by GPI-T. GPI-T displaces the C-terminal signal sequence in the proprotein 
substrate with a GPI anchor, forming a new amide bond between the ω site 
carbonyl and the amine from the phosphoethanolamine group on the third 
mannose in the GPI anchor. Figure 1.5 shows the mechanism of this reaction in 
greater detail. 
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subunit of GPI-T is connected to an intellectual disorder.14,15,16 These different 
diseases highlight the importance of GPI anchoring of proteins to normal cell 
biology. This introductory chapter focuses specifically on the connections that link 
GPI membrane anchoring to abnormal cell biology and cancer. 
GPI-T is a complicated and poorly understood enzyme. GPI-T is a 
membrane bound, multi-subunit protein complex found in the endoplasmic 
reticulum (ER). This enzyme contains five known subunits, PIG-K, PIG-T, 
GPAA1, PIG-S, PIG-U in humans5,12,17 (analogous to Gpi8, Gpi16, Gaa1, Gpi17 
and Gab1 in yeast5,12,18,19). PIG-U, the last subunit of GPI-T was identified more 
than a decade ago and yet clear functional assignments for all but one of these 
subunits have remained elusive. The exception is PIG-K (Gpi8): this subunit 
comprises the catalytic machinery of the enzyme.12,20 Understanding how 
changes in gene overexpression participate in tumor onset or progression is 
difficult without a clear picture of the enzyme itself in terms of its structure and 
function. 
 
1.2 The GPI anchor: A substrate for GPI-T 
GPI anchors contain a common core structure that is conserved across 
eukaryotes and contains an ethanolamine phosphate, three mannoses, a 
glucosamine and a phosphatidylinositol group (Figure 1.1). However, tissue- and 
species-specific core modifications and elaborations were identified in GPI 
anchors from different sources.21,22,23,24,25 The complete biosynthetic pathway to  
5	  
	  
	  
	  
produce the GPI anchor was fully revealed by the early 2000’s (Figure 1.2). This 
pathway requires more than 20 gene products, making GPI anchoring of proteins 
one of the most complex and metabolically expensive post-translational 
modifications.9,26,27 The different enzymes involved in GPI biosynthesis have 
been characterized to varying extents.  Most are hydrophobic and reside in the 
ER membrane (recently reviewed by Fujita and Kinoshita).9 
GPI anchors are present in minute amounts in human and fungal cells and 
are also challenging to synthesize and purify. Due to this complexity, small 
nucleophiles like hydrazine, hydroxylamine, and biotin hydrazide were identified 
as useful GPI anchor mimics.28 These GPI anchor surrogates were used early on 
to characterize the reaction catalyzed by GPI-T.  
Because of limitations faced when isolating GPI anchors from their natural 
environments, it has remained challenging to understand the contributions made 
by different monosaccharides or modifications. Syntheses of short series of GPI 
anchor analogues have been reported.29,30 Synthesis of the full-length CD52 
peptide, with its N-linked glycan and most of its GPI anchor, was reported about 
10 years ago and was recently followed up by the synthesis of a complete GPI 
anchor (from the human lymphocyte CD52 antigen).31,32 These synthetic 
compounds (full-length anchors, synthetic GPI anchored proteins, anchor mimics 
and anchor analogues) can be used not only to better understand GPI-T but also 
to investigate the functions of GPI anchored proteins in cells and for vaccine 
development. In fact, synthetic GPI glycans were used in microarray studies to 
examine antitoxic malaria responses and to develop carbohydrate-based 
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Figure 1.2: Biosynthetic pathway for GPI anchors in human nucleated cells. 
The GPI anchor is synthesized in the ER starting from phosphoinositol. At least 
ten enzymes are needed for this pathway; these enzymes are summarized in the 
table 1.1. The first two steps of the synthesis take place on the cytoplasmic side 
of the ER and steps 4 through 10 occur on the luminal side. Later steps in this 
pathway can vary in different types of cells. 
Cytoplasm
Lumen
(1) (2)
(4)
(3)
(5) (6) (7) (8) (9) (10)
Phosphate 
Inositol 
Glucosamine 
Mannose 
Ethanolamine  
N-acetyl glucosamine
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vaccines to treat severe malaria.33,34 Another recent study used an azide-labeled 
N-acetylgalactosamine analog (GalNAz) to understand the immobilization of GPI 
anchored proteins inside the cell as well as to analyze the functional roles of 
branch modifications.35 
Defects in different GPI anchor biosynthetic steps cause several types of 
inheritable and acquired diseases. For a recent review see Almeida et.al..36 To 
our knowledge, defects in GPI anchor biosynthesis have not been directly linked 
to cancer onset or propagation.  However, patients with paroxysmal nocturnal 
hemoglobinuria (PNH), a hemolytic disorder that results from a somatic mutation 
in PIGA (See Table 1.1), are at increased risk of developing acute leukemia.14 
 
1.3 Protein substrates for GPI-T 
Proteins designated to be GPI anchored are ribosomally synthesized as 
preproproteins and contain an N-terminal signal sequences targeting them for 
translocation into the ER. Historically, it has been assumed that substrates for 
GPI-T enter the ER via the secretory recognition particle (SRP).37 However, a 
recent report made the compelling argument that these preproproteins are 
predominantly delivered to the ER by an SRP-independent pathway.38 This 
process relies on recognition of both the N-terminal signal peptide and the C-
terminal GPI-T-specific signal sequence (described below). Once the 
preproprotein is delivered to the ER, the N-terminal signal sequence is cleaved 
by signal peptidase. The resultant proprotein is recognized by GPI-T and the C-  
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Table 1.1: Enzymes involved in GPI anchor biosynthesis in human 
nucleated cells. Additional modification reactions are known to occur in other 
types of cells. 
 
Step Enzyme complex Proteins involved 
1 GPI-GlcNActransferase39,40,41,42 PIG-A, PIG-C, PIG-H, PIG-P, PIG-Q, PIG-Y, DPM2 
2 GlcNAc-PI de-N-acetylase41 PIG-L 
3 Flippase43 Unknown 
4 Inositol acyltransferase44 PIG-W 
5 α1-4 mannosyltransferase I45,46 PIG-M, PIG-X 
6 α1-6 mannosyltransferase II47 PIG-V 
7 EtNPtransferase I48 PIG-N 
8 α1-2 mannosyltransferase III49 PIG-B 
9 α1-2 mannosyltransferase IV50 PIG-Z 
10 EtNPtransferase III51 PIG-O, PIG-F 
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terminal GPI-T signal sequence is displaced upon conversion to the mature GPI 
anchored protein (Figure 1.3 and Table 1.1). The use of an SRP-independent 
pathway for translocation to the ER clearly defines GPI membrane anchoring as 
a post-translational protein modification. 
GPI-T recognizes and cleaves the C-terminal signal sequence of the 
proprotein at the ω-site, forming a new amide bond between the ω-site carbonyl 
and the appropriate amine on the GPI anchor. The ω-site is so named because it 
becomes the C-terminal residue of the mature GPI anchored protein. This 
residue is immediately followed by the ω+1 and ω+2 residues (and so forth 
towards the C-terminus); the remainder of this C-terminal sequence is composed 
of a hydrophilic spacer and a hydrophobic peptide.52,53 Several studies have 
analyzed the identity of the ω-site amino acid and GPI-T’s ability to tolerate 
substitutions. Most of this work relied on a protein construct called 
preprominiPLAP, a minimalistic version of human placental alkaline 
phosphatase.  PreprominiPLAP promoted significant advances in the field 
because it contained an engineered poly-Met sequence suitable for metabolic 
labeling with 35S-Met and it was significantly smaller than native PLAP so that the 
different processing intermediates could be resolved by gel electrophoresis 
(namely, the preproprotein, the proprotein, and the GPI anchored protein, as well 
as a truncated hydrolytic product).54,55 Analysis of preprominiPLAP mutants 
revealed that alanine, cysteine, glycine, asparagine and serine are good ω-site 
candidates for human GPI-T. Similar results were obtained using human decay  
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Hydrophobic 
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region
Hydrophobic 
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Small Amino 
Acid Domain
(b) The ProProtein
(c) The GPI anchored Protein
Soluble domain of the protein ω
 
 
Figure 1.3: Cartoon schematic of a protein substrate for GPI-T and its 
processing intermediates. The preproprotein (a), which is destined for GPI 
anchoring, has an N-terminal signal sequence that is cleaved by signal peptidase 
to produce the proprotein (b). The GPI-T signal sequence on the C-terminus of 
this protein contains a hydrophilic region followed by a hydrophobic region. The 
signal sequence is cleaved by GPI-T between the ω and ω+1 amino acids to 
attach the GPI anchor, producing the mature, GPI anchored protein (c). (Refer to 
Figure 1.1 for the symbols used to designate the GPI anchor.)  
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accelerating factor (hDAF), another GPI anchored protein; in this case, aspartate 
was identified as a good ω-site but cysteine was not.56,57 In general, the ω-site 
residue should be a small, hydrophilic amino acid.54 The first web server to 
predict the presence and identity of ω sites in protein sequences was put forward 
in 1999, with a false positive prediction rate of only 0.3%.58 
The ω+1 position is typically small but can be any amino acid other than 
proline. The requirements for ω+2 are much more stringent.59,54 This position is 
almost always alanine, glycine or serine.59,54 Because the ω to ω+2 positions 
tend to be small amino acids, this region has been referred to as the Small 
Amino acid Domain (SAD).52,59 
The ω+2 residue is followed by the remainder of the GPI-T signal 
sequence. This peptide is typically between 18 and 32 amino acids long and 
ends at the C-terminus of the protein. It can be broken down into two sections, an 
8-12 amino acid spacer sequence that is predominantly hydrophilic, followed by a 
15-20 amino acid hydrophobic sequence.37,52,53 Remarkably, the GPI-T C-
terminal signal sequence does not contain a consensus motif. In fact, in one 
report, completely artificial signal sequences (e.g. Ser3-Thr8-Leu14) were 
appended onto the C-terminus of CD46 and were shown to be viable, enabling 
GPI anchoring in vivo.60 Consequently, recognition of this sequence by GPI-T is 
analogous to recognition of the N-terminal secretory signal sequence by signal 
peptidase, more than it is to the methods used by other co- and post-translational  
modification enzymes to select their substrates. Recent findings suggest that the 
hydrophobicity of the hydrophobic region needs to be marginal compared to type 
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II transmembrane anchors.61 Similarly, the hydrophilic spacer lacks a consensus 
sequence, but the relative hydrophilicity and the length of the peptide play 
important roles.53,60 Amino acids N-terminal to the ω-site are required for GPI 
anchoring but without sequence or size specificity.37,53,62,63 
The smallest known GPI anchored protein is the CD52 or Campath-1 
antigen.  In humans, the full-length CD52 gene encodes a 61 amino acid protein 
that begins with an N-terminal signal peptide that is 24 amino acids in length. 
CD52’s C-terminal GPI-T signal sequence begins with the ω-site at Ser36 and 
proceeds to the C-terminus (Ser61). Thus, the proprotein is 37 amino acids long 
and the fully mature, GPI anchored protein contains only 12 amino acids.64 
Despite the simplicity of the rules that define the GPI-T signal sequence, 
some studies have suggested that GPI-T shows species specificity for its protein 
substrates.65,66,67 General and species-specific prediction algorithms have been 
developed and have revolutionized the ability of researchers to predict not only 
GPI anchoring but also the identity of the one or two most likely ω-sites.58,68,69,70 
One recent GPI-T signal peptide prediction tool demonstrates high accuracy 
using a position-specific scoring matrix (PSSM).71,72 One thing that these in silico 
analyses suggest is the possibility that GPI-T recognizes and processes more 
than one ω-site in a single peptide, leading to subtle heterogeneity during 
maturation. (In other words, a protein substrate with two putative ω-sites might 
be processed at both positions so that a mixture is produced where the anchor 
can be attached at either ω-site.) To our knowledge, the experimental 
identification of processing at more than one ω-site has not yet been observed or 
13	  
	  
	  
	  
reported. However, very few efforts at genome-wide characterizations of 
anchored proteins, particularly with ω-site validation, have been reported, so this 
possibility cannot be rejected at the present time.  
 
1.4 The GPI Transamidase Complex 
Five GPI-T subunits have been identified so far, with homologues in 
eukaryotes ranging from yeast to humans; all five subunits are essential for the 
attachment of GPI anchors to proteins. As mentioned above, these subunits are 
called PIG-K, PIG-T, GPAA1, PIG-S, PIG-U in humans,5,12,17,73 analogous to 
Gpi8, Gpi16, Gaa1, Gpi17, Gab1 in yeast, respectively.5,12,17,18,19 In Trypanosoma 
brucei, PIG-U and PIG-T are replaced by TTA1 and TTA2, two unrelated 
subunits.74 Table 1.2 summarizes the sizes of these different subunits as well as 
their predicted number of transmembrane domains and glycosylation sites for 
orthologs from humans, yeast, and T. brucei. For the remainder of this 
introductory chapter, we will use the names of the human GPI-T subunits unless 
specifically talking about an experiment conducted with GPI-T from other 
species.  
Homologues of PIG-K, GPAA1, and PIG-T are conserved across 
eukaryotes. In yeast, these core subunits can be purified together as a 
complex.18 In contrast, in humans, all five subunits can be isolated together.5 
Based on mutagenic analyses and its similarity to caspases, the PIG-K subunit  
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Table 1.2: Features of GPI-T from humans, S. cerevisiae, and T. brucei. 
Specific references are provided for publications where a given TM domain or 
glycosylation site was predicted or experimentally examined. Asterisks (*) 
indicate glycosylation sites or TM regions that were only predicted in the UniProt 
database. 
 
Subunit Size (kD) Putative glycosylation sites Transmembrane 
regions 
 
Human 
PIG-K75 45.3  - One*  
GPAA176 67.6  Two: N203, N517 Eight  
PIG-S75 61.7  Two: N267*, N370*  Two*  
PIG-T77 65.7  Three: N164, N291*, N327*  One*  
PIG-U75 50.1  -  Nine*  
S. cerevisiae 
Gpi878 47.4  Three: N23a, N256*, N346*  One*  
Gaa179 69.2  Two: N87, N383*b Six  
Gpi1775 60.8  Five: N100*, N170*, N228*, 
N247*, N299*  
Two*  
Gpi1680 68.8  Two: N28a, N184*  One  
Gab175 44.7  -  Eight *  
T. brucei 
TbGpi881 36.7  One: N25  No  
TbGaa182 51.2  -  Six  
TbGpi1682 75.8  -  One  
TTA182 41.9  Two: N79, N259  Two  
TTA282 45.6  -  Six  
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a In yeast, both Gpi8 and Gpi16 contain reasonable N-linked glycosylation sites 
within or immediately adjacent to their N-terminal signal peptides. These sites are 
listed here for completeness but they have not been characterized; they may not 
be glycosylated or may have been cleaved from the protein during N-terminal 
processing. 
bN383 is predicted as a glycosylation site using UniProt75  However, Hamburger 
et al. reported results that argue that this site is not glycosylated.78-79 N383 lies 
between the second and third transmembrane domains of Gaa1 and is 
presumably inaccessible to the glycosylation machinery.  
 
 
was identified as the catalytic active site and is the best characterized of the five 
known subunits.20,83,84 Possible roles for some of the remaining subunits have 
been proposed and are discussed individually below. The hydrophobicity of the 
subunits, the complexity of the GPI-T enzyme, and poor expression levels of the 
different subunits have contributed to the lack of progress in further 
characterization of this enzyme. Another drawback has been the lack of a high-
throughput assay for GPI-T. Nearly all methods to assay this enzyme’s activity 
are both cumbersome and qualitative. Significant data is accumulating that 
supports the hypothesis that the GPI-T complex contains more than one copy of 
some or all of its subunits. In particular, native PAGE analysis of the pure, 
heterotrimeric GPI-T complex from yeast revealed that this complex resolves into 
two assemblies with molecular weights of ~430 and ~650 kD.18 Given the 
molecular weights of the individual subunits, a complex of only ~240 kD is 
predicted. All three of these yeast GPI-T subunits (Gpi8, Gaa1, and Gpi16) 
contain probable glycosylation sites (See Table 1.2), but it seems unlikely that 
glycans could account for an increase in MW of the ~400 kD needed to explain 
the 650 kD complex. Thus, Conzelmann and colleagues proposed higher order 
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oligomerization for GPI-T.18 The human GPI-T complex (from HeLA cells) has a 
velocity sedimentation value of 17S, also consistent with a globular complex with 
a mass of ~450 kD.85 In this work, Gaa1 was also observed to interact with α- 
and β-tubulin; thus the possibility that tubulin is the source of the increase in the 
molecular weight of GPI-T in humans cannot be ruled out. (Tubulin was not 
apparent in the yeast GPI-T complex analyzed by native gel.) Additionally, PIG-
K, the active site subunit of GPI-T, has sequence and putative structural similarity 
to caspases. The soluble domain of Gpi8 (the PIG-K ortholog from yeast) partly 
assembles into a homodimer when heterologously expressed in Escherichia coli, 
analogous to caspase dimerization.83 Gpi16 is attached to Gpi8 by a known 
disulfide bond86 (see below); thus, by analogy, the hypothesis that the Gpi8 
homodimer is symmetrically modified by two Gpi16 subunits is intuitive. Gpi8 
dimerization has recently been called into question (discussed further in the next 
section).12, 84 Understanding the stoichiometry and organization of GPI-T is going 
to be crucial to understanding its function. Additional research is needed in this 
area. 
The next sections summarize what is known about the structures and 
functions of the individual subunits of GPI-T. The possible functional roles for 
each subunit, as they are currently understood, are discussed individually here 
and are summarized for human GPI-T in Table 1.3. Their possible roles in cancer 
will be discussed later in this introductory chapter. 
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Table 1.3: Proposed functional roles for the five subunits of human GPI-T. 
 
Subunit Possible Roles or Functions 
PIG-K20,78,87 
Similarities to caspases and other cysteine proteases 
Contains all or some of the enzyme’s catalytic machinery 
Attached to PIG-T by a disulfide bond 
GPAA176 May contain part of the active site and be involved in peptide binding and/or recognition 
PIG-S88,89 Essential for thioester intermediate formation between PIG-K and the protein substrate 
PIG-T87,88 
Essential for carbonyl intermediate formation between PIG-K and 
the protein substrate 
Attached to PIG-K by a disulfide bond 
PIG-U5,90 
Loosely associated with the rest of the GPI-T complex 
Weak similarity to fatty acid elongases 
Possibly involved in lipid recognition or binding 
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1.4.1 The PIG-K (Gpi8) subunit 
PIG-K is the catalytic subunit of GPI-T. This ~47 kD subunit nominally 
belongs to the C13 cysteine protease family.12,20 PIG-K has a large soluble 
domain, oriented to the luminal side of the ER, and a single C-terminal 
transmembrane region (Figure 1.4 (a)).12 The soluble domain has sequence 
similarity to caspases, a family of cysteine proteases that regulate cell death.20 
Analysis of conserved His and Cys residues indicated that His164 and Cys206 
are the catalytic residues in human PIG-K (His157 and Cys199 in yeast).20,91 By 
analogy to cysteine proteases, the histidine presumably deprotonates the 
cysteine, which nucleophilically attacks the amide bond between the ω and ω+1 
residues, creating a thioester intermediate, which is subsequently converted to a 
new amide with the GPI anchor (Figure 1.5).92 
A Rosetta-predicted structure of the soluble domain of yeast Gpi8 was 
built based on putative structural homology between caspases and Gpi8 (Figure 
4 (b)).83 This model positions the backbones of the two catalytic residues of GPI-
T (His157 and Cys199) in similar locations and orientations as their counterparts 
in caspases. Caspases are active as homodimers, leading to the hypothesis that 
Gpi8 also assembles into a homodimer, an oligomerization step that may be 
essential for enzyme activity. Dimerization of the soluble domain of Gpi8 was 
observed by native PAGE and by mass spectrometry. Furthermore, dimerization 
was disrupted by the introduction of mutations at positions corresponding to the 
face of caspase dimerization. Significant Gpi8 monomer was also observed in 
this work, leading to the proposal that the Gpi8 dimer reflects the native  
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Figure 1.4: The PIG-K subunit. (a) PIG-K has a single soluble domain (~340 
amino acids) and one transmembrane domain. Human PIG-K is not glycosylated 
however there are three sites of N-glycosylation in yeast Gpi8. The catalytic 
cysteine (Cys206 in humans) is noted. PIG-K is connected to PIG-T via a single 
disulfide bond (not shown). (b) The soluble domain of PIG-K has putative 
sequence and structural homology with caspases.83, 93 The structure of caspase-
1 from Spodoptera frugiperda(PDB: 1M72, green) is overlayed onto a Rosetta 
model of S. cerevisiae Gpi8 (magenta).83 (c) The sequences for portions of the 
active site of human PIG-K (NP_005473), S. cerevisiae Gpi8 (NP_010618), 
human caspase-14 (NP_036246), and S. frugiperda caspase-1 (AAC47442) 
were aligned using Clustal W. Conserved residues are colored in blue, including 
the histidine and cysteine that form the catalytic dyad for each enzyme. Residues 
highlighted in magenta indicate positions that show similarity in at least three of 
the four sequences. (d) A close up of the catalytic dyads in S. frugiperda 
caspase-1 (green) and the model of S. cerevisiae Gpi8 (magenta) from panel B. 
The active site cysteine in caspase-1 is shown alkylated by an irreversible 
inhibitor. The model of Gpi8 places the His/Cys catalytic dyad within hydrogen 
bonding distance. 
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Figure 1.5: Proposed mechanism for GPI-T mediated protein 
transamidation. 
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oligomerization state and that the monomer represents poorly folded or misfolded 
Gpi8 as a consequence of heterologous expression in E. coli. Toh et al. recently 
reported a very similar isolation of the soluble domain of Gpi8.84 However, they 
used size exclusion chromatography (SEC) to isolate only the monomeric form of 
Gpi8. It is unclear whether or not they examined their preparations for dimer and  
it is probable that the Gpi8 dimer was lost during SEC purification. As discussed 
above, clear evidence from two other research groups also support the 
hypothesis that GPI-T assembles into a higher order oligomer in yeast and in 
humans.18,85 Consequently, the preponderance of available evidence argue that 
GPI-T assembles into a higher order oligomer. However, additional 
characterization of this enzyme’s stoichiometry is clearly mandated.  
 
1.4.2 The GPAA1 (Gaa1) subunit 
GPAA1 (67 kD) was the first subunit identified in the GPI-T complex.19 It 
has a single N-terminal TM domain, a soluble domain, and six C-terminal TM 
domains (Figure 1.6).19 GPAA1 shares 25% sequence identity and 57% similarity 
with yeast Gaa1.76 It assembles into a stable complex with Gpi16 and Gpi8 in 
yeast.18 In human cells, GPAA1 associates with PIG-K, PIG-T, PIG-S and PIG-U 
and is essential for transamidase activity.17,85,91 A portion of the soluble domain of 
yeast Gaa1 (residues 70-247) was characterized recently using small angle X-
ray scattering (SAXS) providing a low resolution map of a fragment (residues 70-
247) of this domain.94 
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Figure 1.6: The GPAA1 structure. GPAA1 has one N-terminal transmembrane 
domain, a single soluble domain (~323 amino acids) and six C-terminal 
transmembrane domains.95 Two N-linked glycosylation sites are found in GPAA1 
at Asn203 and Asn517. 
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While its exact function is unknown, evidence suggests that GPAA1 
recognizes and stabilizes the C-terminal signal sequence of the peptide substrate 
through a conserved Pro609 in the last transmembrane helix.85,96,90 Additionally, 
photo cross linking studies also support the hypothesis that GPAA1 interacts with 
protein substrates for GPI-T. GPI-T from GPAA1 knockout mouse cells were still 
capable of generating the thioester intermediate between Gpi8 and a substrate 
protein, but this intermediate was not processed to the mature, GPI anchored 
protein.91 Combined, these observations are consistent with GPAA1 containing 
part of the active site (in addition to Gpi8) and/or a substrate recognition domain. 
However, with all these finding, a recent paper claimed that GPAA1 is a M28 
peptide synthetase that carry presumably a Zn2+ metal binding site and catalyzes 
peptide bond formation between the substrate and the GPI anchor. 
 
1.4.3 The PIG-T (Gpi16) subunit 
PIG-T is a 69 kD protein with a large N-terminal hydrophilic region and a 
C-terminal transmembrane domain (Figure 1.7).17 A mutation in PIG-T is 
connected to a recessive intellectual disability syndrome, which, to our 
knowledge, is the only known GPI-T defect associated with a disease other than 
cancer.16 In yeast, Gpi16 is co-purified along with GST-Gpi8 and Gaa1; in human 
all five subunits co-purify as a complex with GST-PIG-K.5,18 Even though the 
exact function of this subunit is not clear, PIG-T is essential for formation of the 
carbonyl intermediate between Gpi8 and the protein substrate during 
transamidation (see Figure 1.5).17 Some evidence suggests that PIG-T stabilizes  
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Figure 1.7: The PIG-T structure. PIG-T has one N-terminal soluble domain 
(~506 amino acids) and a single C-terminal transmembrane domain. PIG-T is 
connected to PIG-K via a disulfide bond (not shown). PIG-T has three N-linked 
glycosylation sites in its soluble domain. 
PIG-­‐T
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PIG-K and GPAA1: When PIG-T was knocked out, reduced expression levels of 
the other GPI-T subunits were observed.17 PIG-T makes a functionally relevant 
disulfide bond with PIG-K through two conserved cysteine residues, Cys92 (in 
PIG-K) and Cys182 (in PIG-T), making it the only subunit covalently linked to the 
catalytic subunit.86 This linkage is not essential for the formation of the GPI-T 
complex, but is important for GPI-T activity.86 
 
1.4.4 The PIG-S (Gpi17) subunit 
PIG-S is a 61 kD protein with a large soluble domain in between two 
transmembrane regions (Figure 1.8).17 In yeast, Gpi17 is essential for GPI-T 
activity, but it does not stably interact with the core GPI-T subunits (Gpi8, Gpi16, 
and Gaa1) and its exact function is unknown.89 As observed with PIG-T, 
knockout of the PIG-S gene eliminated formation of the thioester intermediate 
between PIG-K and the proprotein substrate.17 PIG-S is one of the subunits 
replaced by TTA1 and TTA2 in T. brucei (See Figure 1.8). 
 
1.4.5 The PIG-U (Gab 1) subunit 
PIG-U was the fifth (and presumably final) subunit identified as a 
component of GPI-T (Figure 1.8).5 This 38 kD protein is highly hydrophobic and 
has between eight to ten transmembrane regions. Deletion of this gene inhibits 
the formation of cell surface GPI anchored proteins.5 Vainauskas and Menon 
suggested that PIG-U is more loosely associated with the GPI-T complex than 
any of the other subunits, based on differential immunoprecipitation patterns with  
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Figure 1.8: Subunits PIG-S and PIG-U are found in human GPI-T (a) and are 
replaced by TTA1 and TTA2 in T. brucei (b). PIG-S and TTA1 are not related in 
sequence but have topological similarities and both contain two putative 
glycosylation sites.  PIG-U and TTA2 both have two small soluble domains and 
several transmembrane domains however they are topological dissimilar and do 
not share sequence similarity. 
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digitonin versus Nonidet-solubilized microsomes.90 Although its contribution to 
the GPI-T complex is unknown, PIG-U does show weak sequence similarity with 
fatty acid elongases suggesting that it may be involved in recognition of the lipid 
portion of the GPI anchor.5 PIG-U was the first GPI-T subunit found in human 
cancer.4 Like PIG-S, PIG-U is also replaced by TTA1 and TTA2 in the T. brucei 
GPI-T (see Figure 1.8). 
 
1.4.6 The TTA1 & TTA2 subunits 
Two of the five human GPI-T subunits (PIG-S and PIG-U) are not 
conserved across all eukaryotes. In trypanosomes, these two subunits are 
replaced by the Trypanosomatid Transamidase 1 (TTA1) and Trypanosomatid 
Transamidase 2 (TTA2) proteins (Figure 1.8).74 TTA1 has two transmembrane 
helices, one at each terminus. The intervening hydrophilic soluble region is 
predicted to face the luminal side of the ER and contain two N-glycosylation 
sites. TTA2 contains multiple transmembrane domains and a single soluble 
domain. TTA1 and TTA2 do not share sequence homology with any mammalian, 
yeast, plant, insect or nematode GPI-T subunits; however orthologs are present 
in Leishmania major. TTA1 and TTA2 are linked to each other through a disulfide 
linkage and knockout of either of these subunits inhibits the transfer of the GPI 
anchor onto its protein substrates.  
The relevance of TTA1 and TTA2 to a discussion of GPI-T and cancer is 
not immediately obvious. However, these two trypanosomal subunits have 
replaced PIG-S and PIG-U, the same two subunits that do not co-purify as part of 
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a robust complex from Saccharomyces cerevisiae.18 Even though we don’t yet 
understand the impact of these observations, they do suggest that the roles of 
PIG-S and PIG-U in human GPI-T may be peripheral compared to those of PIG-
K, PIG-T, and GPAA1. In other words, they hint that PIG-K, PIG-T, and GPAA1 
may constitute the catalytic core of GPI-T for all species. While this hypothesis 
remains speculative, it is likely that these observations will ultimately contribute to 
our understanding of human GPI-T function and the roles of these subunits in 
cancer. 
 
1.5 GPI-T and cancer 
The amplification of oncogenes contributes to human carcinogenesis.97 
Chromosomes 8q and 20q are frequently amplified in many cancers including 
breast, bladder, ovarian and endometrioid carcinomas.98,99,100,101,102 Out of the 
five GPI-T subunits, the genes encoding PIG-U, PIG-T and GPAA1 are localized 
in the 20q11, 20q13 and 8q24 chromosome regions, respectively, positions that 
are considered hotspots for most cancers.103 The genes encoding PIG-K and 
PIG-S are located at 1p31 and 17p13, respectively.103 Simple localization of a 
gene within an oncogenic amplicon is insufficient to identify an oncogene. 
Amplicons contain multiple genes, not all of which have increased copy numbers 
in the corresponding tumors nor are overexpressed to a significant degree. 
However, known oncogenic amplicons make useful starting points to identify new 
oncogenes and to better understand tumorigenesis. 
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The first hint for the importance of GPI-T in cancer was reported by Trink 
and colleagues in 2004, with their discovery of the first oncogenic GPI-T subunit, 
CDC91L1 (encoding PIG-U) in bladder cancer.4 With this finding, the possibility 
of overexpression of other GPI-T subunits in different cancer types came into the 
picture. Another critical study showed that breast cancer cells have significantly 
elevated levels of cell surface GPI anchored proteins that are more typical of 
mesenchymal stem cells than of healthy breast tissue.104 This finding is 
consistent with overexpression of one or more GPI-T subunits leading to up-
regulation of GPI-T catalytic activity as a mechanism for tumor initiation or 
invasion. This section will discuss our current understanding of the 
overexpression of different GPI-T subunits in different cancer types, at both the 
mRNA and protein levels, and their importance as oncogenes or biomarkers. It is 
clear that a number of different downstream events can be activated or regulated 
by overexpression of different GPI-T subunits.  
 
1.5.1 PIG-U and Cancer 
PIG-U was the fifth subunit identified in the GPI-T complex, a hydrophobic 
protein that is essential for GPI-T activity.5 Building on the discovery of germline 
translocation of the 20q11 chromosomal region in uroepithelial cancer, the 
CDC91L1 (PIG-U) gene was characterized for its role in bladder cancer 
development.4,105 This gene lies adjacent to the germline translocation site. 
Overexpression of PIG-U in mice induced tumorigenesis, providing strong 
evidence that this subunit acts as an oncogene.4 Furthermore, forced 
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overexpression of PIG-U in cell culture induced an increase in cell growth rate 
and enhanced overexpression of proteins known to be GPI anchored. Of 
particular interest was the observed overexpression of urokinase plasminogen 
activated receptor (uPAR).4 This GPI-anchored protein is a well-characterized 
oncogene for most cancers.106,107 Increased STAT-3 phosphorylation was also 
observed as a downstream effect of uPAR overexpression, suggesting that 
tumorigenicity arises from perturbations in JAK/stat cell signaling.4 In total, this 
report suggests that overexpression of PIG-U increases GPI-T activity and 
anchoring of substrate proteins although the mechanism by which activity is 
increased remains unknown, particularly since PIG-U is not the catalytic subunit 
of GPI-T.  
A subsequent study concluded that CDC91L1 is not overexpressed in 
urothelial cell carcinomas (where 2.4% overexpression of CDC91L1 mRNA was 
observed compared to > 30% CDC91L1 amplification in cell lines and primary 
bladder tumors.4,108 Finally, a third group assessed a larger data set of bladder 
urothelial cell carcinoma.  In this study, CDC91L1 mRNA was overexpressed in 
30.1% of tumors compared to healthy cells. PIG-U protein overexpression 
occurred in 75.3% of tumor samples.109 These differences in overexpression 
levels of both mRNA and protein presumably arise from different factors such as 
tumor stage, age and gender of the patient, or other environmental factors that 
remain poorly understood. 
Expression patterns for all five GPI-T subunits were analyzed in 19 
different cancer types and compared to healthy tissues from the same organ and 
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the same patient using microarray technology.103 Basal level expression of 
different subunits varied in different types of healthy tissue.103 PIG-U mRNA was 
overexpressed in 60% of colon and ovarian cancer samples versus healthy 
tissue.103 In lymph node tumors, PIG-U protein was expressed at moderate to 
low levels in 90% of malignant tissues, but was not detectable in the 
corresponding healthy tissues. Also a significant increase of PIG-U protein 
production was observed in both ovarian and breast cancer cells and 
overexpression occurred in 60% of large cell lung carcinoma cells.103 PIG-U was 
overexpressed in 42% of breast cancer cells, as well as in prostate cancer.103,110 
 
1.5.2 PIG-T and Cancer 
The PIGT gene is also positioned in a chromosomal hot spot 
(chromosomal region 20q13.12). With the discovery of PIG-U as an oncogene, 
the possibility of other GPI-T subunits as oncogenes, including PIG-T, became 
relevant.4,103 Overexpression of PIG-T was first found in human breast cancer. An 
increase in PIG-T expression correlated with downstream overexpression and 
phosphorylation of paxillin, a known cell invasion related and tumorigenic 
protein.110,111,112 
In the same microarray report discussed for PIG-U, PIG-T mRNA 
overexpression was observed in 60% of uterine, 50% of thyroid and melanoma, 
and 30% of breast cancer samples compared to healthy tissues.103 Significant 
PIG-T protein overexpression was observed in colon, thyroid, lung and 
32	  
	  
	  
	  
pancreatic cancers; overexpression at lower levels also occurred in both 
squamous cell carcinoma and lung adenocarcinoma cells.103 
A combination of mass spectrometry, separate siRNA inhibition of PIG-T 
and GPAA1 expression, and separate overexpression of each of these subunits 
led to the identification of nineteen GPI anchored proteins that are specifically 
expressed in breast cancer cells and are either poorly expressed or not 
expressed in healthy breast tissue.104 Eighteen of these biomarkers are present 
in mesenchymal stem cells, suggesting that all or some of these proteins 
facilitate dedifferentiation of breast cancer cells. Furthermore, reduction of either 
PIG-T or GPAA1 levels by siRNA reduced expression levels of the FOXC2 
transcription factor by 80%. Overexpression (by viral infection) of either subunit 
increased expression of FOXC2 at both the mRNA and protein levels.104 The 
authors posited that overexpression of either PIG-T or GPAA1 affects signal 
transduction pathways (presumably by increased expression of a GPI-anchored 
cell surface receptor) that leads to increased FOXC2 expression. FOXC2 is 
overexpressed in breast and colon cancers and is involved in mitochondrial 
biogenesis and increased cell metabolism.104,113 
Cigarette smoke extract (CSE) induces cancer formation in head, neck, 
bladder and breast cells.114 CSE also induces overexpression of three GPI-T 
subunits: PIG-T, PIG-U, and GPAA1. 
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1.5.3 GPAA1 and Cancer 
Frequent amplification in chromosomal region 8q24 in different cancer 
types makes this region a chromosomal hotspot.115,116,117,118 The GPAA1 gene is 
in the 8q24.3 region and thus, like PIG-U, is a possible oncogene.73,76 
GPAA1 mRNA levels were increased 69% in head and neck squamous 
carcinoma and 40% in uterine cancer cells.103,119 Significant overexpression of 
GPAA1 protein was observed in ovary and thyroid cells, along with ~40% 
overexpression in prostate cancer and 10-20% in lung adenocarcinoma cases.103 
PCR-array profiling of 20 pairs of liver tissues (healthy vs. tumor samples) 
identified 117 genes with different expression levels, only seven of which were 
amplified in hepatocellular carcinoma and both hepatitis B virus positive 
carcinoma and hepatitis C virus positive carcinoma.120 GPAA1 was one of these 
seven genes. Amplification was observed at both the mRNA (75%) and protein 
levels (90%).121 
When GPAA1 was overexpressed in breast cancer cells, levels of 
phosphorylated paxillin also increased, thereby activating Brk-mediated 
phosphorylation and promoting cell invasion that is linked to tumor metastasis 
(Figure 1.9).110,112,122 Along with PIG-U and PIG-T, GPAA1 was overexpressed in 
the presence of CSE, which led to initiation of paxillin phosphorylation in head, 
neck, bladder and breast cancers.114 GPAA1 overexpression led to its 
association with the epidermal growth factor receptor (EGFR) and EGFR 
phosphorylation in the presence of epidermal growth factor.114 As a 
consequence, PIG-T and PIG-U were phosphorylated by EGFR. It was proposed 
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that this GPAA1-EGFR interaction and phosphorylation leads to phosphorylation 
of paxillin to induce cancer initiation.114 GPAA1 overexpression was observed in 
a variety of different cancers that did not correlate with overexpression of other 
GPI-T subunits. The connection between GPAA1 and EGFR may explain this 
divergence.114 Elevated levels of GPAA1 also increased FOXC2 protein 
levels.104,113 
 
1.5.4 PIG-K and Cancer 
Human PIG-K is the catalytic subunit of the GPI-T complex.12,20 Compared 
to other subunits, PIG-K resides on a different chromosome (1p31.1), in a region 
that is frequently lost in various human cancers.123 In breast cancer, PIG-K was 
overexpressed in both ovarian (64%) and uterine (67%) cancers.103 However 
PIG-K was down-regulated 50% in both bladder and hepatocellular carcinoma 
cells and 40% in colon carcinoma cells, based on mRNA levels; similar down-
regulation was observed at the protein level (40%, 100%, and 40% 
respectively).103 In order to understand the reason for diminished PIG-K 
expression, all ten PIG-K exons were examined in samples from 45 different 
colorectal cancer patients. A single nucleotide polymorphism at position 
rs1048575 (outside the coding region), which changed C/C to either G/C or G/G, 
was identified that varied with race.124 In contrast, PIG-K was undetectable in 
normal lymph node tissues but accumulated in 65% of lymph node cancer 
samples.103 
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Given the close connections between GPI-T and cancer in general, it is 
perhaps surprising that PIG-K, the catalytic subunit of GPI-T, is more likely to be 
down-regulated than up-regulated in many cancers. In yeast, depletion of Gpi8 
causes changes in actin morphology (depletion of Gab1, but none of the other 
GPI-T subunits, showed similar effects).125 These changes offer one possible 
scenario for how reduced Gpi8 expression might lead to downstream 
tumorigenesis without increasing GPI-T activity and anchoring of oncogenic GPI 
anchored proteins.  
 
1.5.5 PIG-S and Cancer 
The PIG-S gene resides in chromosomal region 17p13.2, a region lost in 
certain cancers.123 However, PIG-S is overexpressed in breast cancer tissues 
compared to healthy tissues.103 A significant overexpression of PIG-S protein 
was seen in thyroid cancer samples and mRNA levels of PIG-S were amplified 
60% in lung, 40% in ovarian and liver, and 50% in thyroid cancers.103 
 
1.6 How does GPI-T subunit overexpression lead to cancer? 
Overexpression of each GPI-T subunit has been observed in one or more 
cancer types with different frequencies and different patterns. For example, in 
breast cancer samples, PIG-T, PIG-U and GPAA1 are commonly overexpressed 
compared to healthy tissue. In ovarian tumor samples, PIG-T, PIG-K, and 
GPAA1 were overexpressed. In some colon cancer samples, PIG-T is 
overexpressed, but PIG-K expression suppressed.103  Table 1.4 highlights some  
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Table 1.4: Examples of reported changes in GPI-T subunit expression 
(compared to healthy cells of the same tissue).  
 
Cancer Type PIG-U PIG-T PIG-K GPAA1 PIG-S 
Bladder Cancer103,109 ↑↑↑  ↓↓   
Breast Cancer103,126 ↑↑ ↑↑ ↑  ↑ 
Colon cancer103  ↑ ↓↓   
Head and neck squamous 
carcinoma119    ↑↑↑*  
Hepatocellular carcinoma103   ↓↓↓  ↑↑* 
Hepatitis positive 
hepatocellular carcinoma121    ↑↑↑  
Lymph node cancer103 ↑  ↑↑↑   
Lung carcinoma103 ↑↑↑ ↑  ↑ ↑↑↑* 
Melanoma  ↑↑*    
Ovarian cancer103 ↑  ↑↑↑ ↑ ↑↑* 
Pancreas cancer103  ↑    
Prostate cancer103 ↑   ↑↑  
Squamous cell 
carcinoma103  ↑    
Thyroid cancer103  ↑↑*  ↑ ↑↑* 
Uterine cancer103  ↑↑↑* ↑↑↑ ↑↑*  
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Symbols are as follows: ↑↑↑ indicates >50% overexpression; ↑↑ indicates 20-50% 
overexpression; ↑ indicates 0-20% overexpression; ↓↓↓ indicates >50% down-
regulation; ↓↓indicates 20-50% down-regulation; * indicates data obtained from 
mRNA levels (all other data reflect characterization of protein expression levels). 
  
 
examples of the patterns of subunit expression observed in different tumor types 
and samples. 
The five GPI-T genes have the hallmarks of oncogenes, tumor 
biomarkers, and potential targets for the development of new chemotherapeutics. 
However, a great deal remains to be understood before GPI-T subunits can be 
used to detect or treat cancer. For example, how does overexpression of one 
subunit induce tumorigenesis? The work described above has led to proposals 
for different mechanisms (Figure 1.9). First, and most logically, overexpression of 
a GPI-T subunit can lead to increased GPI-T activity and increased presentation 
of GPI anchored proteins on the surface of cancer cells.  
The observation that PIG-U overexpression increased uPAR cell surface 
presentation and Jak/STAT cell signaling supports this hypothesis.4,107 So does 
the fact that GPAA1 overexpression in breast cancer correlated with increased 
cell surface presentation of 18 GPI anchored proteins involved in cell 
dedifferentiation.104 Second, overexpression of GPI-T subunits can cause 
perturbations in cell signaling and transcription that facilitate tumor growth. 
Evidence is accumulating to support roles for GPI-T in modulating paxillin 
phosphorylation and overexpression of the FOXC2 transcription factor.104,114 
Neither paxillin nor FOXC2 is GPI anchored so the subunit overexpression 
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FOXC2 
PIG-­‐T PIG-­‐K GPAA1 PIG-­‐S PIG-­‐U
Induces mitochondrial 
biogenesis & increased 
metabolic activity
(c)
 
 
Figure 1.9: Proposed mechanisms for how GPI-T may participate in cancer: 
(a) Overexpression of uPAR to upregulate the JAK/STAT phosphorylation 
pathway; (b) Activation of paxillin phosphorylation; (c) Upregulation of FOXC2 
expression and downstream signaling. The solid lines represent pathways that 
have more direct experimental support. The dashed lines represent pathways 
that likely involve intermediate steps that are currently uncharacterized. 
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mechanism that leads to these perturbations is not clear. The apparent 
recruitment of EGFR to the GPI-T complex upon GPAA1 overexpression is 
perhaps the most intriguing observation.114 This association led to phosphorylate 
of both PIG-T and PIG-U.  It isn’t known how these phosphorylation events 
impact GPI-T activity, however expression of these different subunits and 
recruitment of EGFR correlated with paxillin phosphorylation.114 
It is clear from these efforts that changes in GPI-T subunit overexpression 
impact the concentrations of different cell surface GPI anchored proteins and 
modulate signal transduction. The specific perturbations in GPI-T that lead to 
these consequences remain poorly understood. For example, is EGFR involved 
in the dedifferentiation of breast cancer after GPAA1 overexpression? Or do the 
GPAA1/EGFR interactions induce tumorigenesis via a mechanism that is 
different from GPAA1-induced dedifferentiation? And, at a more basic level, how 
does overexpression of each subunit impact GPI-T activity? It is easy to 
hypothesize that GPI-T activity is up-regulated in all cases, but this hypothesis is 
contraindicated by the fact that PIG-K, the catalytic subunit, is actually down-
regulated in many tumors.  
With respect to tumorigenesis and GPI-T, it is clear that we are still looking 
at only the tip of the iceberg. Further cell biology studies are needed, in addition 
to a careful assessment of the impact of subunit overexpression on GPI-T 
activity, which was one of the goals in this dissertation. 
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1.7 Functions of GPI anchored proteins relevant to tumorigenesis 
GPI anchored proteins participate in diverse functions including immune 
responses, embryogenesis, fertilization, cell wall biosynthesis, signal 
transduction, and others.127,128,129,130 The medical relevance of GPI anchored 
proteins is clear because specific GPI anchored proteins are crucial for tumor 
growth and invasion as well as other diseases like Creutzfeldt-Jakob disease, 
bovine spongiform encephalopathy, and African sleeping sickness.4,7,131,132 
The following section discusses the physiological functions of a few GPI 
anchored proteins in cancer along with their potential relevance as oncogenes, 
biomarkers, and therapeutic targets. This section does not represent a 
comprehensive list of GPI anchored proteins in cancer. Instead, it is meant to 
highlight the different ways that GPI anchored proteins are known to participate 
in tumorigenesis and cancer progression. The importance of these proteins in 
cancer also implicates GPI-T, or its individual subunits, as targets for the 
development of new chemotherapies. The challenge with targeting GPI-T for 
cancer treatments, however, is that any suitable drug would likely have to access 
the ER to be effective. Thus, GPI-T may prove to be a difficult drug target, but 
changes in the expression of GPI anchored proteins in cancers, like those 
described below, offer an additional set of potential targets. 
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1.7.1 Urokinase plasminogen activated receptor (uPAR) 
uPAR belongs to the urokinase plasminogen activating system (uPAS), 
which also includes the urokinase plasminogen activator (uPA), and two serine 
proteinase inhibitors, plasminogen activator inhibitor-1 (PAI-1) and -2 (PAI-2). 
uPAR is a ~60 kD glycoprotein that is GPI anchored.133 It has three domains, D1, 
D2 and D3, linked together by conserved disulfide bonds.107 In healthy tissues, 
uPAR is expressed at moderate levels; strong expression is seen in tissues 
undergoing extensive remodeling.134 uPAR regulates extracellular proteolysis by 
binding to uPA and activating plasminogen-generating plasma.135 Because of the 
above properties, uPAR is overexpressed in almost all cancer types; 
upregulation of uPAR causes downstream changes in a number of different cell 
signaling pathways (some of which are described below).106,136,137,138,139,140 
Different expression levels of components of the uPA system act as 
biomarkers for different cancers and these receptors and enzymes can serve as 
therapeutic targets.141,142 The most effective way to use this system is by 
inhibiting uPA using small molecule inhibitors or by interfering with the uPA/uPAR 
interaction. Small molecules such as 3-amidinophenylalanine negatively affect 
the uPA system and thereby limit the invasiveness of head and neck carcinoma 
cells, and cervical and breast cancer cell lines. Soluble uPAR inhibits cell 
proliferation in ovarian cancer.143,144 Catalytically inactive uPA fragments and 
peptide constructs that can be used as antagonists or toxins were also useful in 
treating uPAR-activated cancer cells.145,146 
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1.7.2 Glypican-3 
Glypicans are GPI anchored heparin sulfate proteoglycans that regulate 
the activity of heparin binding growth factor.147 So far, six glypicans have been 
identified in mammals, all of similar size (60-70 kD).147 Mutations that takes place 
in Glypican-3 can cause loss-of-function, leading to Simpson-Golabi-Behmel 
syndrome, a rare X-chromosome-linked overgrowth defect.148 The expression 
levels of glypicans differ in growth stage and tissue specific manners, however 
expression predominates during development and in developmental 
morphogenesis.149,150 
The ability of glypicans to regulate growth and survival indicates their 
relevance in tumor progression. The first relationship between cancer and 
glypicans was seen in human pancreatic cancer, where glypican-1 was 
overexpressed.151 Glypican-3 is overexpressed in hepatocellular carcinoma and 
in the clear cell carcinoma of ovaries.132,152 However, down-regulation of 
glypican-3 was observed in breast, lung and ovarian cancer cells.153,154,155 The 
high expression levels of glypican-3 in both hepatocellular and ovarian clear cell 
carcinoma have led to the evaluation of this protein as a therapeutic target using 
cell- and antibody-based immunotherapies with some promising results.156,157,158 
Its differential overexpression in different cancers suggests that glypicans can be 
used as biomarkers using immunohistochemistry and they may be suitable as 
therapeutic targets. 
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1.7.3 Folate binding receptor  
Two folate binding receptors (FR) are GPI anchored glycopeptides that 
have high affinity to folic acid (Kd ~ 1 pM).159 Four different isoforms of FRs are 
known (α, β, γ andδ), however only the α and β isoforms are GPI anchored.160,161 
FR-α is the most widely studied isomer, which has limited expression levels in 
normal tissues but is overexpressed in a variety of cancer cell types including 
ovarian, lung, breast and others.162,163,164 Due to its high affinity for folic acid, the 
FR/folate interaction has been used in radiopharmacology, chemotherapy, and 
magnetic resonance imaging.165,166,167 
During the last two decades, folate-based radioconjugates have been 
developed to use in PET and SPECT imaging and tested in clinical trials in 
patients with folate receptor positive solid tumors.168,169 Several radioisotopes 
have been used for PET imaging, including fluorine-18, gallium-68, terbium-152 
and scandium-44.170,171,172,173 The EC90 vaccine has been used in folate immune 
therapy and is in phase I studies for patients with renal cell cancer.174 Several 
folate receptor targets have been synthesized to use in chemotherapeutics. For 
example, folate conjugate EC145 is in phase I clinical studies for patients with 
refractory tumors.175,176 Overexpression of the folate receptor α in lung cancer 
(72% in adenocarcinomas and 51% in squamous cell carcinomas) indicates the 
importance of the folate receptor as a therapeutic agent and the need for more 
investigation of this GPI anchored protein.162,177 
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1.7.4 Prostasin 
Prostasin is a serine protease highly expressed in the kidneys, prostate 
and lungs.178 It is a GPI anchored protein that acts as a channel activating 
protease-1 (CAP-1) and activates epithelial sodium channels, which maintain the 
salt and fluid balance in the kidneys.179,180 Prostasin is down-regulated in gastric 
and prostate cancer cells but it is overexpressed in pancreatic, breast and oral 
cancer cells.181,182 Recently prostasin has been identified as a potential tumor 
marker for early stages of ovarian cancer.183 Even though the role of prostasin in 
cancer cells is not well understood, the use of prostasin inhibitors such as 
protease nexin–1 (PN-1) have been investigated.184 
 
1.8 Dissertation research  
GPI anchored proteins play vital roles in different cancers and correlate to 
changes in GPI-T expression. Even though the importance of GPI anchored 
proteins in cancer is well established, the importance of GPI-T came into the 
picture only in 2004 with the discovery of PIG-U as an oncogene in bladder 
cancer. Since this discovery, several interesting findings have shown that the 
expression levels of different GPI-T subunits are highly variable in different 
cancer types and between patients. One key question that needs to be 
addressed is how the underexpression of PIG-K or Gpi8, the catalytic subunit, 
affects the GPI-T function in a way that promotes tumors. A detailed knowledge 
of GPI-T structure and function is needed in order to understand the role of this 
enzyme in cancer. To answer this difficulty, I have simplified the complexity of the 
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GPI-T core subunits to facilitate studies of this critical enzyme in my dissertation 
work. Here we used only the soluble domains of the core subunits to analyze the 
structure and function of each subunit alone and with respect to interactions with 
other core subunits.  
Chapter 2 describes the characterization of Gpi8, the catalytic subunit of 
GPI-T. Here we looked at the dimerization of Gpi823-306, the effect of N-linked 
glycosylation on Gpi823-306 dimerization, and analysis of single point mutations 
along the predicted dimer interface of Gpi823-306 on dimerization. This chapter 
showed a robust Gpi823-306 dimerization when overexpressed and purified from 
both yeast and E. coli. Also, the N-linked glycosylation didn’t have any effect on 
Gpi823-306 dimerization and the single point mutations done on the predicted 
dimer interface of Gpi823-306 couldn’t disrupt the dimer completely. 
  Chapter 3 examines interactions between the three core subunit soluble 
domains (Gpi823-306, Gaa150-343 and Gpi1620-551). Using co-immunoprecipitation 
and co-purification methods, we demonstrated that each pair of subunits can be 
isolated as a heterodimer and that the three soluble domains assemble into a 
heterotrimer. 
 Chapter 4 quantifies the impact of subunit overexpression on GPI–T 
activity in vivo. All five subunits overexpressed in cancer in varying levels. 
Therefore it is important to look at how each subunit overexpression affect on 
GPI-T activity. Here we use invertase reporter assay with three different 
Invertase variants having three C-terminal signal sequences to check the GPI-T 
activity when each of the core-subunits are overexpressed. For the three variants 
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overexpression of each GPI-T subunit showed a pattern of changes in GPI-T 
activity. 
Chapter 5 concludes this dissertation with a discussion of the interesting 
questions about GPI-T that remains unanswered and could be examined in the 
future. 
Two appendices are included that describe results from smaller, side 
projects. Appendix A describes our efforts in the synthesis of peptides and 
characterization of GPI-T in vitro assay products using ESI-MS. Appendix B 
summarizes our efforts to characterize the tetramer formation with yeast Gpi823-
306 and Gaa150-343. 
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CHAPTER 2 
GPI81-306 DIMERIZATION: EFFECTS OF N-LINKED GLYCOSYLATION AND 
ANALYSIS OF THE PREDICTED DIMER INTERFACE 
 
2.1 Introduction 
Being the catalytic subunit, Gpi8 plays an important role in the GPI-T 
complex. Even though Gpi8 is the most well characterized subunit in GPI-T, 
questions have been raised over the last five years about the structure and 
function of this subunit in terms of stoichiometry and its the catalytic activity.83-84, 
92, 185-186 Therefore further characterization of Gpi8 is still required for a complete 
understanding of GPI-T to be achieved. 
Full-length yeast Gpi81-411 is a 47 kD protein that belongs to the C13 
cysteine protease family. It contains a catalytic dyad (His 157 and Cys 199) that 
is believed to create a thioester intermediate with the ω-site residue of each 
protein substrates for GPI-T (see Figure 1.5). Rosetta software was used to 
construct a tertiary model of the soluble domain of Gpi8. This model overlaid 
nicely onto the structure of caspase-1 from S. frugiperda, even these two 
proteins share only very low level sequence similarity (~6%) (Figure 1.4).83,187  
In order to better understand about this protein, yeast Gpi823-306 was first 
overexpressed and purified using E. coli to obtain higher levels of protein 
expression.83 Here we used only the soluble domain I of Gpi823-306 without its N-
terminal signal sequence, according to the Rosetta model. Purified Gpi823-306 was 
shown to exist as a mixture of homodimer and monomer, leading to the proposal 
that Gpi8 assembles into a homodimer analogous to caspases.83 At this time, we 
hypothesize that the monomer was inadvertently formed either because of the 
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truncation of this subunit (e.g. the transmembrane domain would further drive 
dimerization) or as a result of heterologous expression in E. coli (e.g. 
glycosylation would help induce dimerization).  This dimerization model was later 
questioned by a group of scientists from Singapore, who demonstrated that 
Gpi824-334 was monomeric.84 However, this group purified Gpi824-334 by size 
exclusion chromatography (SEC), and apparently did not look for the dimer in 
their SEC experiment, suggesting that the dimerized fraction might have been 
lost during purification.  
Here, we set out to more robustly characterize Gpi8 dimerization using 
native polyacrylamide gel electrophoresis (PAGE), SEC followed by native PAGE 
analysis and electrospray ionization ion mobility separation mass spectrometry 
(ESI-IMS-MS). Additionally because GPI-T is a eukaryotic enzyme, we 
hypothesized that expression in E. coli might fail to generate robustly folded 
proteins, leading to the mixture of monomer and dimer that we observed 
previously. Therefore we used S. cerevisiae to homologously overexpress and 
purify yeast Gpi81-306. In this case, Gpi8 was overexpressed with its N-terminal 
signal sequence (residues 1-22) to facilitate its processing through the secretory 
pathway. The above mentioned techniques were also used to analyze the effect 
of N-linked glycosylation on the dimerization of Gpi81-306 and to analyze the 
predicted dimer interface. Still when Gpi81-306 was expressed in yeast, a mixture 
of dimer and monomer was obtained. Dimerization was stable to mutations at the 
N-linked glycosylation site indicating that glycosylation does not drive 
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dimerization. Mutations at the predicted dimer interface only partially disrupted 
dimerization.  
 
2.2 Results 
2.2.1 Purification optimization of yeast Gpi823-306 over-expressed in yeast 
During canonical protein secretion, proteins translocated into the lumen of 
the ER undergo glycosylation and folding with the assistance of chaperones and 
enzymes.188 Misfolded proteins undergo ER associated degradation in the 
proteosome and folded proteins are transported through COPII (coat protein II) to 
their appropriate destinations.188 Full length Gpi8 is located in the ER membrane, 
with its soluble active site domain in the ER lumen.  
We imagined that the soluble domain I of Gpi81-306, when overexpressed 
without its transmembrane domain, might be secreted into the extracellular 
medium. To test this idea, yeast Gpi81-306-V5- His6 (in pYES-DEST52 vector, 
InvSc1 cell line) was overexpressed in yeast and Ni-NTA affinity purification was 
used to isolate Gpi81-306-V5- His6 from the cell pellet and the growth medium. (we 
assume that the N-terminal signal sequence, residues 1-22, have been cleaved 
from this construct, converting Gpi81-306-V5- His6 into Gpi823-306-V5- His6. 
(However, this cleavage has not verified.) Gpi823-306-V5- His6 was not secreted 
into the growth medium, however it was isolated from cells in low amounts 
(Figure 2.1 (a)). 
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Figure 2.1: Gpi823-306-V5- His6 is not secreted into the growth medium. (a) 
Anti-V5 blot of an SDS-PAGE gel (12%) showing Gpi823-306 expression levels in 
the cell pellet (P) versus the growth medium (M); both after Ni-NTA affinity 
purification. Lane 1: molecular weight markers, lanes 2, 4 and 6: purified proteins 
from pellets when overexpressed for 12, 18 and 24 hours after induction, lanes 3, 
5 and 7: proteins purified from the growth medium after overexpressing for 12, 18 
and 24 of induction. Three glycoforms of Gpi823-306 were observed in lanes 2, 4 
and 6. Lanes 3, 5 and 7 did not contain any detectible Gpi823-306, indicating that 
this protein is not secreted to the growth medium. (b) Confirmation of the 
presence of Gpi823-306 using Coomassie stain (left) and anti-V5 blot (right). 
Purified yeast Gpi823-306-V5- His6 was used to confirm the presence of Gpi823-306. 
The left panel shows a Coomassie stained gel of purified Gpi823-306 (lane 1: 
molecular weight markers, lane 2: purified protein) and the right panel shows the 
anti-V5 blot of the same protein sample (lane 1: molecular weight markers, lane 
2: purified protein). The band corresponding to Gpi823-306 was excised from the 
Coomassie stained gel, digested with trypsin, and analyzed by mass 
spectrometry. (In collaboration with Dr. Chih-Wei Liu from professor Sarah 
Trimpin’s lab.)    
 
52	  
	  
	  
	  
Following purification to homogeneity, the protein band believed to be 
Gpi823-306 was excised and treated with trypsin to confirm its identity. In-gel 
trypsin digestion and mass spectrometry were conducted by Dr. Chih-Wei Liu in 
Prof. Trimpin’s lab. The protein bands were excised and cleaned (see materials 
and methods section), followed by the analysis of the samples using LC/MS/MS 
(Waters Inc.). The LC/MS/MS results were then uploaded to the Mascot server, 
to search for the matching sequences. An ion score was then calculated as the 
probability of each sequence compared to the matching sequence. The highest 
ion score corresponded to the best matched sequence. All ion scores were 
summed to give the protein score for one distinct sequence (Table 2.1, lane 1), 
which is proportional to the abundance of the protein in one particular sample.  
The band corresponding to Gpi823-306 was identified as a combination of 
alcohol dehydrogenase (ADH1, ADH2 and ADH3) and low levels of Gpi823-306 
(see both Figure 2.1 (b) and Table 2.1). Also ADH1, ADH2 and ADH3 have over 
80% sequence homology. This result was unexpected because the native S. 
cerevisiae ADH is not histidine tagged and should not have been purified by Ni-
NTA affinity purification. However, a published report has indicated that 
overexpression of ADH occurs when using the GAL1 promoter (as in our vector), 
with low levels of glucose.189 ADH has two zinc binding motifs and a molecular 
weight of 37 kD which is similar in size to domain 1 of Gpi81-306.95 Since there are 
no known interactions between ADH and Gpi8, we believe that ADH was non-
specifically purified by Ni-NTA affinity chromatography. Therefore considering 
both the low expression levels of Gpi8 and the presence of ADH contamination,  
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Table 2.1: MS/MS analysis of the putative Gpi823-306 protein band indicates 
the presence of a contaminant, ADH. Protein scores were calculated using the 
probability for each of the sequences and the most abundant protein is ADH1. 
Along with ADH, Gpi8 is also present in low quantities. 
 
Protein Score Protein identification Description 
3417 ADH1 S. cerevisiae 
1054 ADH3 S. cerevisiae, Mitochodria 
947 ADH2 Kluyveromyces marxianus 
763 Gpi8 S. cerevisiae 
608 ADH2 S. cerevisiae 
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we have restricted our analysis to anti-V5 Western blots to specifically visualize 
and analyze protein samples containing Gpi823-306-V5-His6.  
 
2.2.2 Homo-dimerization of yeast Gpi823-306-V5- His6 over-expressed in yeast 
versus E. coli 
 We previously reported that Gpi823-306 forms a mixture of homodimer and  
monomer when isolated from E.coli.83 Here we set out to determine whether 
more robust dimerization would occur when Gpi823-306-V5-His6 was expressed in 
S. cerevisiae and purified using Ni-NTA affinity chromatography. GST-Gpi823-306 
was expressed in E.coli and purified by glutathione affinity chromatography for 
comparison. Purified proteins were analyzed using native PAGE and anti-GST 
and anti-V5 Western blots (Figure 2.2). As observed previously,83 when purified 
from E.coli, GST-Gpi823-306 forms a monomer/homodimer mixture (Figure 2.2 
(a)). Quantitatively, a higher ratio of dimer to monomer was observed when 
Gpi823-306 was purified from S. cerevisiae (Figure 2.2 (b)) compared to that from 
E.coli. Additionally, when purified from S. cerevisiae, three Gpi8 glycoforms were 
visible. These glycoforms hindered quantitative analysis of the extent of 
monomer versus dimer. The presence of dimer was confirmed by comparing 
bands to the monomer of Gpi823-306, which was obtained by heating the protein in 
sodium dodecyl sulfate (SDS) gel loading dye to denature the protein.  
 These observations were further corroborated by analyzing GST-Gpi823-
306 purified from E. coli using SEC followed by native PAGE analysis of the 
elution fractions (Figure 2.3).  
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Figure 2.2: Yeast Gpi81-306 when overexpressed in E. coli or S. cerevisiae 
forms a mixture of homodimer and monomer. (a) Anti-GST blot of a native gel 
containing GST-Gpi823-306 when overexpressed and purified from E. coli using 
glutathione sepharose affinity purification. Lane 1: molecular weight markers, 
Lane 2: GST-Gpi823-306 labels indicate the presence of both dimer and monomer 
as labeled. (b) Anti-V5 blot of the native gel of Gpi823-306-V5-His6 overexpressed 
in S. cerevisiae and purified using Ni-NTA affinity purification. Lane 1: molecular 
weight markers, lane 2: denatured Gpi823-306-V5-His6 (see materials and 
methods), lane 3: native Gpi823-306-V5-His6. Glycoforms are visible in both the 
monomer and the dimer bands. Both bands highlight the presence of a mixture of 
dimer and monomer. 
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Figure 2.3: GST-Gpi823-306 purified from E.coli yields a higher amounts of 
dimer compared to monomer when analyzed by SEC.  Analysis of each SEC 
fraction of GST-Gpi823-306 using native PAGE (a) and SDS PAGE (b). (a) An anti-
GST blot of the native PAGE showing both the dimer and monomer for each of 
the SEC fractions. Lane 1: molecular weight markers, lane 2: Denatured protein 
sample, lanes 3-7: SEC fractions. (b) The anti-GST blot of the SDS PAGE for 
each of the fractions analyzed. Lanes are similar to the top (a) panel.    
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Unfortunately, individual peaks representing monomer versus dimer were 
not resolved by SEC. Since the expected dimer is 114 kD and the monomer is 57 
kD, fractions from the SEC column were analyzed from the corresponding size 
range (compared to the SEC marker). Without SEC native gel analysis of the 
purified GST-Gpi823-306 (from E. coli) indicates higher amounts of monomer over 
dimer. However, when these proteins were injected into SEC and then evaluated, 
higher amounts of dimer were visible (Figure 2.3).  
 
2.2.3 The effect of N-linked glycosylation on dimerization of Gpi823-306-V5- 
His6. 
N-linked glycosylation is an important post-translational modification that 
takes place in eukaryotic proteins that enter the secretory pathway and contain 
an aspargine (Asn) residue within an Asn(N)-X-Ser(S)/Thr(T) consensus 
sequence (X can be any amino acid other than proline).190 Glycosylation is 
important for a wide variety of functions such as protein stability, folding, signal 
transduction, proper orientation, cellular trafficking and more.191,192,193,194,195,196,197 
According to the UNIPROT database, full-length Gpi81-411 contains two 
predicted glycosylation sites at N256 and N346. N23 is also an appropriate 
consensus sequence, however, it was not listed as a glycosylation site since it is 
present immediately adjacent to the N-terminal signal peptide and so it was not 
predicted to be a valid site (Figure 2.4 (a)).75 Therefore only the N256 site lays 
within the domain I (Gpi823-306), the region of interest herein. When Gpi823-306-V5-
His6 was overexpressed and purified from S. cerevisiae, three different bands  
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Figure 2.4: Gpi823-306-V5- His6 has two N-linked glycosylation sites within 
the region of our interest. (a) A cartoon representation on the possible 
glycosylation sites of Gpi8. The full length Gpi81-411 has three glycosylation sites 
at N23, N256 and N346. Domain I contains N23 and N256 glycosylation sites. (b) 
Anti-V5 blot of an SDS PAGE gel showing the glycoforms found in Gpi823-306-V5-
His6 and the N256Q and N256A mutants. Lane 1: molecular weight markers, 
lane 2: wild type Gpi823-306-V5-His6 lane 3: N256Q mutant and lane 4: N256A 
mutant. Wild type Gpi823-306-V5-His6 shows three bands corresponding to 
glycosylation at N23, N256 and the unglycosylated form of this protein. Each 
mutant (N256Q and N256A) had two bands consistent with glycosylation at N23 
and the unglycosylated form. (c) An anti-V5 blot of the SDS PAGE gel showing 
the impact of Endo H treatment on Gpi8 glycosylation. The wild type enzyme and 
two mutants were treated with Endo H (see materials and methods). Lane 1: 
molecular weight markers, lanes 2, 4 and 6: deglycosylated wild type Gpi823-306-
V5-His6, N256Q, and N256A, respectively, after Endo H treatment. Lanes 3,5 
and 7: wild type Gpi823-306-V5-His6, N256Q, and N256A, respectively, before 
Endo H treatment. All seven lanes are from one single blot. 
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were observed in the anti-V5 blot (Figures 2.2 & 2.4), suggesting the presence of 
two glycoforms and the non-glycosylated protein. The two glycoforms represent 
multiple glycoforms at N256 or glycosylation at both N256 and N23.   
To evaluate the importance of glycosylation on Gpi8 dimerization, we 
mutated N256 to Gln (Q) and Ala (A). When overexpressed in S. cerevisiae, wild 
type Gpi823-306-V5-His6 showed three bands in the anti-V5 blot, whereas N256 
mutants only had two bands (Figure 2.4 (b)). When the wild type Gpi823-306-V5-
His6 and its two mutants were treated with Endoglycosidase H (Endo H), an 
enzyme that removes N-linked glycans198 all glycoforms condensed into one 
deglycosylated band (Figure 2.4 (c)). These results strongly suggest that N23 is 
also glycosylated. To examine the effect of N-linked glycosylation on Gpi823-306 
dimerization, wild type Gpi823-306-V5-His6, the two mutants, and all Endo H 
treated fractions were analyzed using anti-V5 blots by native PAGE along (Figure 
2.5). In each gel, the corresponding denatured protein was used as a marker. In 
all Gpi823-306 samples, the presence of both dimer and monomer was observed, 
indicating that glycosylation is not essential for dimerization. 
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Figure 2.5: N-linked glycosylation does not affect Gpi8 dimerization. (a) 
Anti-V5 blot of a native PAGE gel of wild type Gpi823-306-V5-His6. Lane1: 
molecular weight markers; lane 2: denatured Gpi823-306-V5-His6 or mutant; lane 3: 
native Gpi823-306-V5-His6 or mutant; lane 4: native Gpi823-306-V5-His6 or mutant 
after treatment with Endo H. Both native forms show a mixture of dimer and 
monomer. (b) Anti-V5 blot of a native PAGE gel of the N256Q mutant. A mixture 
of dimer and monomer was observed even after treatment with Endo H.  Lanes 
are the same as in (a) but only with the N256Q mutant. (c) Anti-V5 blot of a 
native PAGE gel of the N256A mutant. Results were similar to those in panel a 
and b. Lanes are the same as in (a) but with the N256A mutant. The presence of 
a mixture of dimer and monomer in wild type Gpi823-306-V5-His6 and both mutants 
independent of Endo H treatment indicates that N-linked glycosylation does not 
affect dimerization. 
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The Oligomerization states of the N256Q and N256A mutants were also 
examined by SEC (Figure 2.6). Purified N256Q and N256A samples were 
injected into the SEC column. Fractions were analyzed by native PAGE and SDS 
PAGE. Both N256Q (Figure 2.6 (a)) and N256A (Figure 2.6 (b)) contained a 
mixture of dimer and monomer consistent with the gel analyses shown in Figure 
2.5.  
 Additionally, ESI-IMS-MS was used to confirm the formation of the dimer 
in both Gpi823-306-V5-His6 and the N256Q and N256A mutants. ESI-IMS-MS is 
ideal for this type of analysis because ions can be separated based on size 
(shape) and mass.199,200,201,202,203 Nevertheless, it proved challenging to analyze 
the dimer and monomer of Gpi823-306 because of their higher molecular weights 
(unglycosylated dimer: 74 kD, unglycosylated monomer: 37 kD). Glycosylation of 
this protein, yielding the glycoforms shown in Figure 2.5, further complicated the 
analysis. Spectra were collected and analyzed in collaboration with Prof. Sarah 
Trimpin and of Dr. Ellen Inutan (Figure 2.7). The monomer and dimer mixtures 
were also examined by ion mobility separation for Gpi823-306-V5-His6 and the 
N256Q and N256A mutants. Ni-NTA affinity purified proteins were buffer 
exchanged with ammonium acetate (see materials and methods for details) prior 
to analysis. Samples were injected onto the Synapt G2 mass spectrometer for 
ESI-IMS-MS analysis. Two dimensional plots of m/z vs drift time were 
constructed for each protein and are shown in the top panels of Figure 2.7 (a), 
(b) and (c). The middle and bottom panels show mass spectra that can be  
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Figure 2.6: SEC analysis confirmed N256 mutagenesis does not affect 
dimerization. Anti-V5 blots of the native PAGE gel (top panel) and SDS PAGE 
gel (bottom panel) of SEC fractions for the N256Q mutant (a) and the N256A 
mutant (b). Concentrated SEC fractions were analyzed using native PAGE, 
which shows the presence of both dimer and monomer. Lane 1: molecular weight 
markers, lanes 2-9: SEC fractions. Both mutants show dimer and monomer 
consistent with the conclusion that N-linked glycosylation is not required for Gpi8 
dimerization. 
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Figure 2.7. ESI-IMS-MS analysis to characterize the monomer and dimer 
forms of Gpi823-306-V5-His6 and N256Q and N256A mutants. ESI-IMS-MS 
analysis of (a) wild type Gpi823-306-V5-His6; (b) the N256Q mutant; and (c) the 
N256A mutant. In each case, the top panel shows a 2-D plot of m/z vs. drift time. 
Charge states corresponding to the monomer and dimer are noted. The middle 
panel shows an analysis of the mass spectrum from the dimer region in panel 
(a). The bottom panel shows the mass spectrum from the monomer region in (a). 
See Table 2.2 for additional analysis.	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tentatively assigned as dimer and monomer ion clusters (boxed in panels a, b 
and c).  
Different charge states were observed that are also consistent with 
separation of monomer and dimer for all three proteins (summarized in Table 
2.2). However, presumably because of the higher molecular weights of the dimer 
and monomer and the different glycosylation states, broad peaks were observed 
and the ions were of very low abundance. Nevertheless, deconvolution of 
different ion clusters yielded interpretable molecular masses for the N256Q and 
N256A mutants. Using the masses calculated for the two mutants, the size of the 
glycans on N256 in wild-type Gpi823-306-V5-His6 was calculated to be ~3000 
g/mol (Table 2.2, Figure 2.7). These results are preliminary, given the low 
abundance of the observed ions. Efforts to improve ionization have been 
unsuccessful. 
 
2.2.4 Predicted dimerization interface analysis using single point mutations 
Activation of caspase 1, a cysteine protease, plays an important role in 
innate immune response.204 Inactive monomeric pro-caspase-1 is activated 
inside the cell, after undergoing a process of dimerization and auto-proteolysis.205 
Structural similarities between	  our Rosetta model of	  domain 1 of Gpi8 (Gpi823-306) 
and S.	  frugiperda (Figure 1.4) led us to hypothesize that Gpi8 would also exist as 
a dimer.83 We constructed a crude model of the Gpi823-306 dimer by overlaying 
the Rosetta model of Gpi823-306 onto the S. frugiperda caspase-1 dimer structure 
(Figure 2.8 ) to predict the dimer interface.    
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Table 2.2: Summary of the observed charge states for Gpi823-306-V5-His6	  and 
the N256Q and N256A mutants. Molecular weights were calculated from the 
different charge states for each protein’s monomer and dimer using the m/z 
values assigned to each broad peak by the Drift Scope software. The X denotes 
changes in mass that presumably arise from glycosylation at N256.  
Protein complex Observed charge states
Calculated 
MW (Da)
Observed 
MW (Da)
N233Q dimer 20+, 21+,22+,23+,24+ 74255 74321
N233Q monomer 12+,13+ 37127 37125
N233A dimer 20, 21+,22+,23+,24+,25+,26+ 74141 74291
N233A monomer 12+,13+,14+ 37070 37097
Wild type dimer 24+,25+,26+ 74227 + 2X 80626
Wild type monomer 13+,14+,15+ 37113 + X 39921
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Figure 2.8: Dimer of Rosetta modeled Gpi81-360 created using caspase-1 
dimer.  
 
 
 
 
 
 
 
 
 
67	  
	  
	  
	  
Monomer 
Dimer 
Monomer 
Dimer 
Monomer 
Dimer 
Monomer 
Dimer 
Monomer 
Dimer 
Anti-V5, Native PAGE Anti-V5, Native PAGE Anti-V5, Native PAGE
Anti-V5, Native PAGE
Anti-V5, Native PAGE
Y168A mutant Y184A mutant F187A mutant
H249A mutant
P190A mutant
Monomer 
Dimer 
Anti-V5, Native PAGE
F275A mutant
Monomer 
Dimer 
Anti-V5, Native PAGE
H253A mutant
(a) (b) (c) (d)
(e) (f) (g)
1 2 3 1 2 3 1 2 3 1 2 3
1 2 3 1 2 3 1 2 3
Monomer 
Dimer 
Anti-V5, Native PAGE
Wild-type
(h) 1 2 3
 
 
Figure 2.9: Single point mutation analysis on the predicted dimer interface.  
Each image is of an anti-V5 Western blot of native PAGE gels of each of the 
seven mutants: (a) Y168A mutant, (b) Y184A mutant, (c) F187A mutant, (d) 
P190A mutant, (e) H249A mutant, (f) H253A mutant and (g) F275A mutant. (h) is 
the wild type Gpi823-306-V5-His6 for the comparison. For each gel, lane 1: 
molecular weight markers; lane 2: denatured protein; lane 3: native protein. For 
some images (F187A, P190A, H249A, H253A, and F275A), intervening lanes 
from the blot were removed for clarity. These changes are indicated by the 
presence of a white space separating the different lanes. The complete, 
unadulterated blots are included in an appendix (Appendix C, Figure C.1) at the 
end of this dissertation.  
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Seven single point mutations were created by Megan Ehrenwerth at the 
predicted dimer interface. After overexpression and purification from S. 
cerevisiae, each point mutation was analyzed using native PAGE (Figure 2.9). 
The glycoforms hindered our ability to quantify the amount of dimer and 
monomer for each mutant. However, qualitatively, different ratios of dimer to 
monomer were present for the different mutants. None of the	   point mutations 
completely disrupted Gpi823-306 dimerization. However, the	   P190A and H253A 
had the largest effects (Figures 2.9 (d) and	   (f)). Molecular weight markers and 
denatured proteins were used as controls.  
 
2.3 Discussion 
All the experiments described herein were conducted with Gpi823-306 that 
had either been expressed in E. coli (GST-Gpi823-306) or in S. cerevisiae (Gpi823-
306-V5-His6). Results confirming our earlier findings and clearly show that Gpi823-
306 assembles into a homodimer.2 Gpi8 dimer was observed by native PAGE and 
SEC. SEC analysis demonstrated that dimer predominates in this mixture. This 
was for Gpi823-306 that had been purified from E. coli using glutathione sepharose 
affinity purification (Figure 2.2 & 2.3) as well as for the N256 mutants of Gpi823-
306-V5-His6 mutants that were overexpressed in S. cerevisiae and purified using 
Ni-NTA affinity purification (Figure 2.5 & 2.6). These results strongly suggest that 
the dimer to monomer ratio observed in vitro depends on the protein’s 
surrounding environment. However, complete dimerization was not observed 
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with any samples, suggesting that dimerization might be further driven by domain 
II or the transmembrane domain, which were deleted in our constructs. 
As discussed, full-length yeast Gpi81-411 contains three possible 
glycosylation sites: N23, N256 and N346. However, N23 is immediately adjacent 
to the N-terminal signal sequence and so it was predicted that this site would not 
be glycosylated. The work presented herein represents the first efforts to 
characterize the N256 glycosylation site in terms of protein expression, stability, 
and its possible participation on dimerization. The elimination of N-linked glycans 
at 256, either by mutagenesis or Endo H treatment, did not eliminate 
dimerization, demonstrating that glycosylation and dimerization are separate, 
disconnected events. The results from this analysis also gave the first indication 
that N23 is glycosylated even though it is adjacent to the signal sequence. 
Presumably, glycosylation occurs prior to cleavage of residues 1-22 by signal 
peptidase. However, N-terminal signal sequence cleavage was not confirmed in 
this work.  
None of the single point mutations that were made at the predicted dimer 
interface didn’t completely dimerize (Figure 2.9). The P190A and H253A mutants 
noticeably disrupted dimerization in favor of monomer. It is possible that the 
structural changes introduced by these single point mutations are insufficient to 
completely disrupt dimerization. Analyses of double and even triple point 
mutations are expected to shed further light on this question. 
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2.4 Materials and methods 
2.4.1 Buffers and solutions 
Phosphate buffered saline (PBS): 10 mM Na2HPO4, 1.8 mM KH2PO4, 140 
mM NaCl, 8.7 mM, pH 7.3. GSH elution buffer: 100 mM reduced glutathione 
(GSH), 50 mM Tris HCl, pH 8.0. Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, 5% glycerol, pH 7.4. Wash buffer: 50 mM NaH2PO4, 1 M NaCl, 50 
mM imidazole, 5% glycerol, pH 7.4. Elution buffer: 50 mM NaH2PO4, 300 mM 
NaCl, 300 mM imidazole, 5% glycerol, pH 7.4. Tris glycine: 25 mM Tris base, 200 
mM glycine, pH 8.3. 10X transfer buffer: 0.4 M glycine, 0.5 M Tris base, 13 
mM sodium dodecyl sulfate (SDS). 1X transfer buffer: 10X transfer buffer was 
diluted to 1X in 20% aqueous methanol. Tris-Buffered Saline and Tween 20 
(TBS-T): 10 mM Tris HCl, 150 mM NaCl, 0.05% Tween, pH 7.5). SEC buffer: 50 
mM NaH2PO4, 300 mM NaCl. Minimal medium (4X Sc-ura): 26.8 g Yeast 
nitrogen base, 6.4 g dropout mix, 0.4 g each adenine, leucine, tryptophan and 
histidine in 1L of water and sterile filtered before use. 
 
2.4.2 Over-expression and purification of yeast Gpi823-306 from E. coli 
Plasmid pJLM008 (encoding GST-Gpi823-306) was transformed into 
BL21(DE3) RIL Codon Plus cells (Stratagene).83 Protein overexpression was 
carried out with an overnight culture (30 mL) which was grown at 37 °C in Luria 
Bertani (LB) medium, and used to innoculate 1 L of LB medium that had been 
supplemented with 50 µg/mL ampicillin (Sigma-Aldrich). This culture was grown 
at 19 °C to an OD600 of 0.4-0.5, and then induced with 1 mM isopropyl-γ-D-1-
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thiogalactopyranoside (IPTG, Gold Bio Inc). Cells were pelleted after two hours 
post-induction and stored at -80 °C until ready for use.  
All purification steps were conducted at 4 °C unless otherwise noted.  Cell 
pellets were resuspended in 15 mL PBS supplemented with 15 µL 
phenylmethanesulfonylfluoride (PMSF, from a saturated solution in isopropanol), 
and one quarter tablet of protease cocktail inhibitor (Roche). The suspension was 
lysed using an ultrasonic cell disrupter (Microsone) with six pulses for 20 sec 
each a power of 4 with 40 sec rest period in ice in between each pulse. The 
lysate was spun down at 14,000 rpm for 1 hr in a Beckman JA-20 rotor. The 
supernatant was supplemented with 500 µL (bed volume) pre-washed 
glutathione sepharose fast-flow resin (GE-Amersham Biosciences). The cell 
lysate supernatant and resin mixture was incubated for 1 hr at room temperature.  
The resin was washed ten times with 5 mL PBS each time. The expressed 
protein was eluted from the resin by treatment with 2 mL GSH elution buffer for 
10 minutes at room temperature. The eluted protein solution was removed from 
the resin and concentrated to 250 µL. Elutions were loaded directly onto a 12% 
SDS-polyacrylamide gel for analysis before they were used for further 
subsequent experiments. 
 
2.4.2 Over-expression and purification of yeast Gpi823-306 from yeast 
All plasmids encoding for wild type Gpi823-306-V5-His6, and the nine 
mutants studied herein (N256Q, N256A, Y168A, Y184A, F187A, P190A, H249A, 
H253A and F275A) were inserted into the pYES-DEST52 destination plasmid 
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using Gateway cloning technology (Invitrogen). These constructs were prepared 
by Megan Ehrenwerth. Briefly, the gene fragment coding wild type was amplified 
from genomic DNA using two primers flanking with AttB regions on either side. 
The resultant gene product was inserted into a donor vector (pDONR221) 
following the BP reaction according to the manufacturer’s instructions 
(Invitrogen). This insert	   was sequenced in its entirety. The insert was then 
transferred into the destination vector (pYES-DEST52) using the LR reaction 
according to the manufacturer’s instructions. This plasmid introduced the C-
terminal V5 and six histidine tags	  onto Gpi81-306.This plasmid was used as the 
parent plasmid to create all the nine mutants using QuikChange site directed 
mutagenesis (Qiagen). The complete insert was resequenced after consruction 
of each mutant.  
Plasmids were then transformed into the S. cerevisiae strain, INVSC1 
(Invitrogen) using standard yeast transformation protocols (Invitrogen). In order 
to overexpress  Gpi823-306 and each of the different mutants, an overnight culture 
(50 mL) was grown at 30 °C in Sc-Ura (minimal medium that lacks uracil) and 1% 
glucose. This culture was used to inoculate 1 L of Sc-Ura medium with 1% 
galactose in a 4 L flask. The culture was incubated at 30 °C. Cells were 
harvested after 12 hours and the final OD600 was noted for use in during 
purification. 
 All purifications were conducted at 4 °C. Typically, a cell pellet from a 4 X 
1L growth was resuspended in 10 mL lysis buffer and lysed using glass beads 
using a bead beater (Invitrogen), for 8X30 s pulses with 30 s rest periods in ice in 
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between pulses. The lysate was centrifuged at 3000 rpm for 10 min to remove 
the cell debris and glass beads and the supernatant was centrifuged for 1 hour at 
14,000 rpm in a Beckman JA-20 rotor. The filtered, clear supernatant was 
passed through a 1 mL Ni-NTA high trap column (GE Health care) followed by 
wash steps with 5 column volumes of lysis buffer and 50 column volumes of 
washing buffer. Finally, the protein was eluted using 5 mL of elution buffer and 
the eluted fraction was concentrated to 100 µL. The fractions were analyzed 
using 12% SDS-PAGE gel and other techniques. 
 
2.4.3 Analysis of the oligomerization state of Gpi823-306 and its mutants by 
native PAGE and Western blots 
All proteins were analyzed via an 12% SDS-PAGE or 10% native PAGE 
gels. Proteins were kept for 30 min on ice prior to loading onto the native gel. 
Electrophoresis was carried out with a 10% native polyacrylamide gel (39:1 
Acrylamide:bisacrylamide, at pH 8.8) in tris-glycine buffer for 3 hours at 4 ºC at 
100 V. Bands were visualized by Western blot using an anti-V5 antibody (Sigma-
Aldrich). 
For all Western blots, the proteins were transferred to the membrane 
(Immobilon-FL, Millipore) as follows:. The membrane was soaked in 100% 
methanol for 5 min and was transferred into 1X transfer buffer and incubated for 
15 mins. For native PAGE 0.15% W/V SDS was added to the1x transfer buffer. 
The gel was also put in the 1X transfer buffer with the membrane for 15 min. Six 
blotting papers were cut to the same size as the gel and were immersed in the 
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same buffer prior to the transfer. A semi-dry Western blot apparatus (Thermo 
Scientific) was used for the transferring of proteins from the gel to the membrane. 
Three blotting papers were placed on the anode plate followed by the gel, 
membrane and another three blotting papers carefully without introducing any air 
bubbles. One gel (8.5 cm X 10 cm) was transferred to the membrane for 30 min 
at 200 mA.  
 The transferred membrane was incubated for two hours or overnight in 
5% milk in TBS-T prior to incubation with the primary anti-V5 antibody (Sigma-
Aldrich, 0.5 µg/mL in 1% BSA) or the anti-GST antibody (Anaspec, 0.5 µg/mL in 
1% BSA) for 2 hr. The membrane was washed 3X with 50 mL TBS-T incubating 
for 5 min each time. The membrane was then incubated with anti-mouse IgG 
Hilyte Plus 647 (Anaspec, 0.5 µg/mL in 1% BSA) for 1 hr. the membrane was 
washed again 3X with 50 mL TBS-T with an incubation of 5 min each time and 
then the blot was visualized using a Typhoon 9210 (Red 633 nm excitation laser, 
670 nm emission filter). 
 
2.4.4 Analysis of Gpi823-306 protein secretion to media in yeast 
Cells were grown at 30 ºC as described above. For each time point, a 500 
mL aliquot of the cell culture was removed. Cells were harvested at 3500 rpm for 
5 min using a Beckman F-500 rotor. The medium was transferred to a 1 L flask 
and NaH2PO4 and NaCl were added to final concentrations of 50 mM and 300 
mM respectively. The pH was adjusted to 7.0  and one half of a protease cocktail 
inhibitor tablet (Roche) was added to inhibit any proteolytic activity. A precipitate 
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formed as the pH was adjusted. The mixture was filtered using a 0.2 µm filter and 
the precipitate was discarded (after verification that it did not contain Gpi8 by 
SDS-PAGE, data not shown). The filtered medium was treated with Ni-NTA resin 
as described above to purify any secreted Gpi823-306. For comparison, Gpi8 was 
also purified and analyzed from cell pellets. 
 
2.4.5 Removal of glycans using Endo H 
Purified Gpi8 and mutant samples were treated with Endo H to remove 
any N-linked glycans. For 30 µL of a protein sample, 0.5 µL of Endo Hf (1000 
U/µL, Invitrogen) were added. The digestion was carried out for 2 hours at 30 ºC. 
Proteins were incubated at 4 ºC for at least 30 min prior to analysis by native 
PAGE. 
 
2.4.6 Evaluation of dimers using size exclusion chromatography (SEC) 
 A sample of 100 µL of protein (~50 µM) was buffer exchanged with SEC 
buffer, filtered using a 0.22 µm filter, and injected onto an ultra high resolution 
SEC column (14 mL, Waters) using a BioRad FPLC system. The column was run 
with 3X column volume with a flow rate of 0.25 mL/min or 0.3 mL/min. Fractions 
were collected, concentrated and analyzed using 12% SDS-PAGE and 10% 
native PAGE followed by corresponding blot analysis as described above. A gel 
filtration standard (100 µg, SEC marker, BioRad) was used to generate a 
standard curve. 
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2.4.7 Use of ESI/IMS/MS to evaluate dimer formation by Gpi823-306 
 Samples for mass spectrometric analysis were quantified using a Bradford 
assay (BioRad). Each protein was diluted to a concentration of 5 pmol/µL in 25 
mM ammonium acetate buffer with 10% methanol for the analysis by the ESI-
IMS-MS using a SYNAPT G2 HDMS from Waters Inc. Each sample was injected 
at a flow rate of 10 µL/min and drift time and m/z (mass to charge ratio) data 
were collected for 20 min. Driftscope 2.1 (Waters) was used to visualize the 2D 
plot of drift time vs m/z ratio using a black background and hot metal color code 
for the third dimension (ion intensity). The data were further processed by 
extracting mass spectral information for the ion peaks of interest. The spectra 
were adjusted one time using the Savitzky-Golay smoothing method with a value 
of ± 10. Baselines in all spectra were subtracted to provide a baseline level close 
to 0%. 
 
2.4.8 In-gel trypsin digestion for protein confirmation    
Protein bands were excised from the gel manually, and washed several 
times with destaining buffer (10% Acetic acid. 45% methanol and 45% water) to 
remove the Coomassie stain. The gel was then cut into small pieces and washed 
twice for five minutes each time with 50 µL of 50% acetonitrile (ACN) in water. 
Next, the pieces were washed in 50 µL of 200  mM NH4HCO3. The gel pieces 
then were shrunk with 100% ACN until they turned white and were dried for 5  min 
in an vacuum evaporator (Genevac).  
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The following steps as well as acquiring spectra were done by Dr. Chih-
Wei Liu from Prof Sarah Trimpin’s lab. The gel pieces were rehydrated in 15 µL 
of 50  mM NH4HCO3 at 37  °C for 4  min prior to trypsin digestion. An equivalent 
volume (15 µL) of  20 ng/µL trypsin (Trypsin Gold, Promega) in 50  mM NH4HCO3 
was added to the gel pieces, and they were incubated at 37  °C for at least 16  h 
for complete digestion. The digests were extracted using 0.1% formic acid in 
50% ACN.  All extracts were dried and dissolved in 50% ACN:water with 1% 
formic acid and analyzed using (LC/MS/MS). The resultant mass spectra were 
uploaded into the Mascot server to analyze proteins.  
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CHAPTER 3 
CO-EXPRESSION AND CHARACTERIZATION OF THE SOLUBLE DOMAINS 
OF CORE SUBUNITS OF GPI-T 
 
3.1 Introduction 
Gab1 was the first subunit of GPI-T discovered to be oncogenic, 
highlighting the importance of this enzyme in cancer.206 However, the complexity 
of the membrane-bound GPI-T enzyme has hindered progress towards 
understanding how it functions. In 2001, the Conzelmann group discovered that 
the full-length GPI-T core subunits, Gpi8, Gpi16 and Gaa1, could be co-purified 
as an intact complex.18 Even though Gpi17 and Gab1 are also essential for GPI-
T activity, they do not form a stable complex with Gpi8, Gpi16, and Gaa1 in 
yeast.89 Unfortunately, 10 years later, scientists still have not determined the 
function of each subunit or the stoichiometry of the complex. These types of 
results would be of general interest	   because of this enzyme’s medical and 
scientific importance. Also, development of a facile assay to investigate GPI-T 
activity has proved to be challenging.  
In order to understand the structure and organization of the GPI-T 
subunits, we want to determine the stoichiometry of each subunit in the GPI-T 
complex. Evidence suggests that GPI-T contains more than one copy of each 
subunit.18,187 We focused only on the core heterotrimeric GPI-T subunits, Gpi8, 
Gpi16, and Gaa1. Our lab has demonstrated dimer formation of the soluble 
domain of Gpi823-306 and several other labs have observed that GPI-T is 
significantly larger (440-660 kD) than the sum of the molecular weights of the core 
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subunits (186 kD, not considering the impact of glycosylation).18,83,85 Combined, 
these observations suggest that GPI-T is at least a Symmetrical dimer, perhaps 
further modified with different glycoforms. The possibility that GPI-T is a dimer 
cannot be entirely ruled out at this point. Despite these observations by us and 
others, our evidence for dimerization of Gpi823-306 was questioned recently, in 
favor of Gpi8 existing as a monomer.84 In response, in chapter 2 of this thesis, 
we further characterized the dimer of Gpi823-306 when overexpressed and purified 
from both yeast and E. coli.  
The approach we used in Chapter 2 eliminated the complexities 
introduced by working with the full-length, membrane-soluble subunits. The native 
transmembrane (TM) regions Gpi8 (1 TM), Gpi16 (1 TM), and Gaa1 (6 TMs) 
make it difficult to purify and analyze these subunits. Therefore, as in chapter 2, 
we used molecular modeling and TM domain predictions to focus only on the 
soluble domain regions of these subunits, i.e. Gpi81-306, Gaa150-343 and Gpi161-
551.83,207 As a precursor to characterizing the stoichiometry of these subunits, we 
first looked at the assembly of each soluble domain into heterodimeric and 
heterotrimeric complexes using co-immunoprecipitation studies. In this chapter 
we show that each possible pair of these soluble domains assemble into stable 
isolable heterodimeric complexes. Additionally, we show that the heterotrimer 
containing at least one copy of Gpi823-306, Gaa150-343, and Gpi1620-551, can be 
purified by tandem affinity purification (TAP), laying the foundation for future 
studies to characterize the stoichiometry of this complex. This complex was 
tested initially for GPI-T activity using an in vitro assay under development in our 
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lab (Appendix A). We observed an increase in fluorescence over time, even in the 
absence of the nucleophile hydroxylamine. Further studies are underway to 
characterize the catalytic activity of this soluble core complex as well as to 
evaluate its stoichiometry.	  
	  
3.2 Results 
3.2.1 Plasmid design and construction 
Yeast Gpi8 contains a larger luminal domain (residues 23-380) that was 
used to create a model using Rosetta software.75,208 (In full-length Gpi8, residues 
1-22 contain the N-terminal ER localization signal sequence, residues 377-397 
contain the TM domain, and residues 398-411 represent a short cytoplasmic 
peptide.)75 The model was built with two domains, domain I (the caspase-like 
domain, residues 23-306) and domain II (a smaller domain, residues 307-376) 
(Figure 3.1).83 The overlay of domain I to that of caspase-1 from Spodoptera 
frugiperda led us to conclude that domain I would likely be sufficient for 
dimerization studies (Figure 1.4). Indeed, our previous publication83 and the 
results in chapter 2 clearly demonstrate that domain 1 assembles into a 
homodimer.  
Similar to Gpi8, Rosetta produced a plausible model for Gaa1, taking into 
account only this subunit’s large soluble domain (50-343 residues) (Figure 3.1). 
(Full-length Gaa1 contains six TM domains; one is N-terminal (residues 20-40) 
and the remaining five are C-terminal (residues 357-598)).75 After expression, the 
N-terminus of wild-type Gaa1 lies in the cytosol. Thus, to express our  
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Gpi81-411 Gaa11-614
Gpi81-306-V5-His6
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pAG305
Leu marker
pAG414
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Figure 3.1: Rosetta modeling and design of soluble domain constructions 
to overexpress Gpi81-306, Gaa150-343 and Gpi161-551. In all three panels, a 
cartoon is shown for each full-length subunit (left) followed by a cartoon of the 
soluble domain construct (or constructs) studied herein. See the accompanying 
text for additional information about the plasmids used to express these vectors. 
(a) A Rosetta model of the soluble domain I of Gpi8 (blue) is shown. Building 
from this model, we cloned the portion of the gpi8 gene coding residues 1-306 
into the pYES-DEST52 vector. (b) A Rosetta model of the soluble domain of 
Gaa1 (red) is shown. Gaa150-343 was cloned into the pAG305-TAP destination 
vector. After N-terminal processing, this vector produces Gaa150-343-TAP. (Note: 
Another Gaa1 construct was also used but proved significantly less essential so it 
is not shown here. See text below for details). (c) A useful Rosetta model was not 
obtained from our modeling efforts. Gpi161-551 was cloned into the pAG414-HA 
expression vector. After processing, this plasmid is expected to produce Gpi1620-
551-HA. 
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truncated version with processing through the ER, we introduced the vacuolar 
protein carboxypeptidase Y (CPY) signal sequence207 to the N-terminus of 
Gaa150-343. 
The soluble domain of Gpi16 (residues 1-551) was similarly analyzed with 
Rosetta after eliminating the single, predicted C-terminal TM domain (Figure 3.1). 
Unfortunately, the model returned by Rosetta was not strong. These Rosetta 
analyses were conducted by Prof. Tamara Hendrickson, Dr. Jennifer Meitzler, Dr. 
Yug Varma, and Megan Ehrenwerth. 83,207 
Dr. Meitzler, Dr. Varma and Ms. Ehrenwerth also constructed the original 
plasmids for the overexpression of these soluble domains. These plasmids are 
described in detail below. Plasmids were constructed using Gateway cloning 
technology. Gpi81-306 and Gpi161-551 were cloned with their native N-terminal 
signal sequences; Gaa150-343 was cloned with the CPY signal sequence 
appended onto its N-terminus. Each gene was initially put into the pDONR221 
entry vector (Invitrogen). The resultant donor vectors were used to transfer these 
genes into the desired destination vectors as outlined in Figure 3.1. Destination 
vectors were selected to contain three different, compatible selection markers (for 
co-expression studies) and for the tags that they would append onto each 
subunit. Protein expression is induced with galactose with all three final 
destination vectors used herein. 
Gpi81-306 was transferred into pYES-DEST52 (Invitrogen) to append V5 
and His6 tags onto the C-terminus of this protein. These tags were used for 
immunoblotting and visualization. The pYES-DEST52 vector contains a Ura 
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selection marker. Gpi161-551 was transferred into pAG414-GAL (Addgene), which 
adds a C-terminal HA tag for immunoblotting experiments. This vector contains a 
Trp selection marker. 
CPY-Gaa150-343 was transferred into either pAG414-GAL, which appends a 
C- terminal HA tag and contains Trp selection marker, or into pAG305-GAL 
(Addgene), which adds a C-terminal TAP tag and contains a Ura marker. As 
described below, challenges arose when expressing Gaa1 from the pAG414-GAL 
vector. Consequently, all subsequent experiments used the pAG305-GAL vector 
coding for Gaa150-343-TAP. 
 
3.2.2 Gaa150-343-HA binds to Ni2+ and Co2+ resin. 
The characterization of Gpi823-306 and Gaa150-343 were conducted using 
proteins purified from InvSc1 cells, an S. cerevisiae cell line. Initial experiments 
(conducted by Dr. Jennifer Meitzler) characterized yeast His6-Gaa150-343 alone 
and with GST-Gpi823-306 after overexpression in and purification from E. coli. 
Several observations were made, namely that expression of His6-Gaa1 alone is 
toxic to E. coli and that the low levels of His6-Gaa150-343 that were present could 
be co-purified with GST-Gpi823-306 by glutathione affinity chromatography.207,209 
To better characterize this heterodimeric complex, we switched from E. coli to S. 
cerevisiae. The plasmids encoding GPY-Gaa150-343-HA and Gpi81-306-V5-His6 
were transformed individually or together into InvSc1, S. cerevisiae and were 
overexpressed using galactose induction. Co-purification studies were initially 
carried out with Ni-NTA affinity purification, to determine whether or not 
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purification of Gpi823-306-V5-His6 would result in co-purification of Gaa150-343-HA, 
confirming what Dr. Meitzler had seen when variations of these two constructs 
were co-expressed in E. coli. Unexpectedly, after purification, Western blots with 
α-HA antibody demonstrated that Gaa150-343-HA was purified by Ni-NTA affinity 
without co-purification of Gpi823-306-V5-His6 (Figure 3.2 (a)). A control experiment 
was conducted with Gpi823-306-V5-His6 in the absence of Gaa1. In this case, 
Gpi823-306-V5-His6 was purified as expected. Further analysis revealed that the 
purification of Gaa150-343 was not due to interactions with Gpi81-306; instead, this 
protein showed affinity for Ni-NTA resin (lane 2 of Figure 3.2 (b)) and also with 
Co2+ resin (Figure 3.2, lanes 3-7). These results were surprising because our 
Gaa150-343 construct did not contain a His6 tag. Sequence alignments with full-
length Gaa1 (not shown) suggest that it is an M28 type aminopeptidase with one 
metal binding site, presumably for Zn2+.186 Perhaps its ability to bind to Ni2+ and 
Co2+ resin arises from this metal binding site. Because of this unexpected 
obstacle, we reversed our approach and used an anti-HA antibody to examine 
Gpi823-306-V5-His6 and Gaa150-343-HA interactions by co-immunoprecipitation 
analyses. 
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Figure 3.2: CPY-Gaa150-343-HA can be purified by Ni2+ and Co2+ resin without 
a His6 affinity tag. (a) Co-purification of CPY-Gaa150-343-HA and Gpi823-306-V5-
His6 using Ni-NTA affinity purification. Top panel: An anti HA blot to confirm the 
presence of Gaa1. Bottom panel: An anti-V5 blot to confirm the presence of 
Gpi8. For both panels, lane 1: Gpi823-306-V5-His6 alone; lane 2: Co-purification of 
CPY-Gaa150-343-HA and Gpi823-306-V5-His6. (b) Results from a mock purification 
of Gaa150-343-HA using Ni-NTA resin. Cell lysate containing overexpressed CPY-
Gaa150-343-HA were incubated with Ni-NTA resin. The results of this purification 
were examined by Western blot using an α-HA antibody. The lanes in this blot 
are as follows: lane 1: molecular weight markers; Lane 2: Gaa150-343-HA purified 
by Ni-NTA affinity chromatography; lanes 3-7 show the results of this mock 
purification using Co2+ resin; lane 3: cell lysate; lane 4: flow through; Lane 5: 
wash; Lane 6: eluted fraction (300 mM imidazole); lane 7: resin after elution. The 
anti HA blot confirms the purification of Gaa150-343 by metal (Ni2+ and Co2+) affinity 
purification without a His6 tag. A picture of the complete blot is shown in 
Appendix C, Figure C.2. 
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3.2.3 Gpi823-306-V5-His6 co-immunoprecipitation with Gaa150-343-HA  
An HA antibody was used to see if Gpi823-306-V5-His6 would co-
immunoprecipitate with Gaa150-343-HA. As controls, we carried out parallel 
immunoprecipitation studies with each subunit alone as well (Figure 3.3). As 
expected, Gpi823-306-V5-His6 alone did not immunoprecipitate from total cell 
lysates with the HA antibody in the absence of Gaa150-343-HA (Figure 3.3, lane 1); 
Gaa150-343-HA alone was immunoprecipitated with the HA antibody (Figure 3.3, 
lane 2). When both Gpi81-306-V5-His6 and CPY-Gaa150-343-HA were 
overexpressed together, immunoprecipitation of Gaa150-343-HA led to the co- 
precipitation of Gpi823-306-V5-His6 (Figure 3.3, lane 3). These results confirm that 
Gpi823-306-V5-His6 interacts with Gaa150-343-HA non-covalently. Consequently, it 
can also be concluded that the interactions between these two subunits do not 
require other GPI-T subunits or transmembrane domains. 
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Figure 3.3: Gpi823-306 interacts with Gaa150-343 without its transmembrane 
domains or the Gpi16 subunit. (a) A cartoon representation of the interactions 
between the soluble domains of Gpi8 and Gaa1. Gpi823-306 co-
immunoprecipitated with Gaa150-343 when both Gpi823-306-V5-His6 and Gaa150-343-
HA were overexpressed together in yeast. (b) Western blot analysis of 
immunoprecipitation results using HA antibodies. Top panel: an anti-HA blot 
confirming the presence of Gaa150-343-HA in different samples after co-
immunoprecipitation. Bottom panel: an anti-V5 blot examining the presence of 
Gpi823-306-V5-His6 in different fractions. Blots were generated from the same sets 
of samples from two different SDS-PAGE gels that were run in parallel. Lane 1: 
Gpi823-306-V5-His6 alone; lane 2: Gaa150-343-HA alone; lane 3: Co-
immunoprecipitation of Gpi823-306-V5-His6 with Gaa150-343-HA; lane4: molecular 
weight markers. For the image, intervening lanes from the blot were removed for 
clarity. These changes are indicated by the presence of a white space separating 
the different lanes. A complete gel picture is shown in Appendix C, Figure C.3. 
These results indicate that the soluble domains of Gpi823-306 Gaa150-343 interact 
with each other in vivo. 
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3.2.4 Gpi823-306 co-immunoprecipitates with Gpi1620-551. 
 The Gpi16 subunit is covalently connected to Gpi8 through a disulfide 
bond, and this interaction has been proposed to maintain complex stability.210 In 
yeast GPI-T, the residues Cys85 of Gpi8 and Cys202 of Gpi16 form this disulfide 
bond.211-212 Even though the exact function of Gpi16 is not known, It has been 
proposed that its lumenal domain of Gpi16 has a β-propeller structure that acts 
as a funnel that directs the protein substrate into the Gpi8 active site.213-214 
To gain further insight into the interactions between Gpi8 and Gpi16, a 
Gpi16 soluble domain was constructed as described above using Gateway 
cloning technology for overexpression in yeast with galactose induction. Gpi16 
has a single C-terminal TM domain (residues 546-568). The Gpi16 construct 
(Gpi161-551) was designed by removing this TM domain leaving the native N-
terminal ER signal sequence intact. Gpi161-551 was cloned into pAG414-GAL 
such that a C-terminal HA tag was added for visualization by Western blot. The 
same Gpi8 construct (Gpi81-306-V5-His6), as described above (Section 3.2, 
Chapter 3), was used here.   
We used an anti-HA antibody for these studies. Gpi81-306-V5-His6 and 
Gpi161-551-HA were overexpressed and immunoprecipitated separately and 
together, the results are shown in Figure 3.4. Gpi823-306-V5-His6 did not show any 
non-specific interactions with either the resin or the antibody (Figure 3.4 (b), lane 
4). As expected, Gpi1620-551 alone was successfully immunoprecipitated using an 
anti-HA antibody (Figure 3.4 (b),lane 5).  
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Figure 3.4: Gpi823-306 specifically co-immunoprecipitates with Gpi1620-551 
indicating formation of a heterodimer between these two subunits. (a) A 
cartoon representation of the putative interactions between the soluble domains 
of Gpi8 and Gpi16 of interest herein. (b) Western blot results from 
immunoprecipitation studies conducted with anti-HA antibodies. The top panels 
show an anti-HA blot to visualize Gpi1620-551-HA. The bottom panels show results 
from an anti-V5 blot to visualize Gpi823-306-V5-His6. Lanes 1-3 contain the lysates 
used in these studies, before immunoprecipitation. Lanes 4-6 show the results 
after immunoprecipitation. Lanes 1 and 4: Gpi823-306-V5-His6 alone; lanes 2 and 5: 
Gpi1620-551-HA alone; lanes 3 and 6: Co-immunoprecipitation of Gpi823-306-V5-
His6. A complete gel picture is shown in Appendix C, Figure C.4. 
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In contrast, when Gpi81-306 was co-expressed with Gpi161-551, these 
subunits co-immunoprecipitated as a complex under oxidizing conditions (Figure 
3.4, lane 6). Co-immunoprecipitation of Gpi823-306-V5-His6 with Gpi1620-551-HA as 
a complex is in contrast to previous findings with human GPI-T that showed that 
interactions between these two subunits require their TM domains.215    
  In wild-type GPI-T, the disulfide bond between Gpi8 and Gpi16 is formed 
between C85 (Gpi8) and C202 (Gpi16). To test the importance of these residues 
for assembly of the Gpi823-306:Gpi1620-551 complex, each cysteine residue was 
mutated to alanine and the co-immunoprecipitation studies described in the 
previous paragraph were repeated. These mutations would eliminate the 
possibility of disulfide bond formation between Gpi8 and Gpi16. Co-expression 
and co-immunoprecipitation studies were conducted with the following protein 
combinations: C85A Gpi823-306 with WT-Gpi1620-551, WT-Gpi823-306 with C202A 
Gpi1620-551, and C85A Gpi823-306 with C202A-Gpi1620-551 (Figure 3.5). In all cases, 
immunoprecipitation of Gpi1620-551-HA using an anti-HA antibody led to co-
immunoprecipitation of Gpi823-306-V5-His6 (Figure 3.5). These results demonstrate 
that the disulfide bond between Gpi8 and Gaa1 is not essential for the 
interactions between the soluble domains of these two subunits.  
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Figure 3.5: The disulfide bond between Gpi8 and Gpi16 is not essential for 
Gpi823-306 and Gpi1620-551 interactions. Immunoprecipitation studies were 
conducted using anti-HA antibody under oxidizing conditions. Each of the lane 
contains both Gpi1620-551-HA and Gpi823-306-V5-His6 either with or without the 
mutant. Lane1: Co-immunoprecipitation of C85A Gpi823-306-V5-His6 with WT 
Gpi1620-551-HA. Lane 2: Co-immunoprecipitation of WT Gpi823-306-V5-His6 with 
C202A Gpi1620-551-HA. Lane 3: Co-immunoprecipitation of C85A Gpi823-306-V5-
His6 with WT Gpi1620-551-HA. The complete picture of this blot is shown in 
Appendix C, Figure C.5. Results indicate that Gpi1620-551 interacts with Gpi823-306 
even in the absence of the disulfide bond between these two subunits.  
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 3.2.5 Gaa150-343 assembles into a heterodimeric complex with Gpi1620-551  
 We also examined the hypothesis that Gpi1620-551 and Gaa150-343 could 
form a stable heterodimer in the absence of Gpi8. Gateway cloning technology 
was used and a plasmid expressing Gpi1620-551 was constructed with a V5 and a 
His6 tag added to its C-terminal. Another plasmid was constructed in which 
Gaa150-343 was modified to contain an N-terminal CPY signal sequence and a C-
terminal tandem affinity purification (TAP) tag. Co-immunoprecipitation with IgG 
resin (targeting the TAP tag) demonstrated that these two subunits also directly 
interact with each other, in this case in the absence of Gpi8 (Figure 3.6). 
However, additional controls needed to be done to confirm that Gpi1620-551-V5-
His6 does not have any non-specific affinity for this IgG resin. 
 
3.2.6 The three core subunits of GPI-T co-purify with each other without 
their transmembrane regions 
The results described above demonstrate that the soluble domains of the 
core subunits of GPI-T stably interact with each other in heterodimeric pairs. 
Building on these results, we set out to isolate these three soluble domains as a 
single complex (Figure 3.7 (a)). Such an accomplishment would open up 
innumerable new avenues to further and better characterize GPI-T. It would be of 
particular interest to determine if such a complex was catalytically active. We 
overexpressed and set out to purify the core complex, containing Gpi81-306-V5-
His6, Gpi161-551-HA and CPY-Gaa150-343-TAP using the InvSc1 strain of S. 
cerevisiae and the plasmids described in previous sections.  
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Figure 3.6: Gpi1620-551-V5-His6 co-immunoprecipitates with Gaa150-343–TAP. 
(a) A cartoon representation of the putative interaction between Gpi161-551 and 
Gaa150-343. (b) Results from immunoprecipitation with IgG resin. The top panel 
shows an anti-TAP blot indicating the presence of Gaa150-343-TAP after 
precipitation with IgG resin. The bottom panel shows an anti-V5 blot 
demonstrating that Gpi1623-551-V5-His6 was isolated with Gaa1. Additional 
controls will be run to confirm that this result arose from specific interactions 
between the two subunits rather than via non-specific interactions between Gpi16 
and the IgG resin. The complete picture of this blot is shown in Appendix C, 
Figure C.6. 
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Figure 3.7: Tandem affinity purification of Gaa150-343-TAP results in the co-
purification of Gpi1623-551-HA and Gpi823-306-V5-His6. (a) A cartoon 
representation of the putative interactions between Gpi823-306, Gpi1620-551, and 
Gaa150-343 of interest herein. (b) Evaluation of the co-purification of Gpi1620-551-HA, 
Gpi823-306-V5-His6, and Gaa150-343-TAP. Each fraction along the purification was 
tested for the presence of the individual subunits using specific antibodies for 
Gpi8 (top), Gpi16 (middle), and Gaa1 (bottom). In all three panels, lane 1: 
molecular weight markers; lane 2: cell lysate prior to purification; lane 3: flow 
through after lysate was incubated with the calmodulin binding resin; lane 4: 
Gaa150-343-TAP after elution from the resin, with its co-purified protein partners; 
lane 5: anti-protein A resin after elution. The complete picture of this blot is 
shown in Appendix C, Figure C.7. 
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This heterotrimeric complex was isolated by TAP tag purification in vitro 
using calmodulin binding resin (see materials and methods). The presence of all 
three soluble domains was verified by Western blots for each subunits (Figure 
3.7). Lanes 2-5 of Figure 3.7 indicates analysis of each fractions along the 
purification. When purified using TAP tag, both Gpi823-306-V5-His6 and Gpi1620-
551-HA purified along with Gaa150-343-TAP as an intact complex (Figure 3.7, lane 
4). These results indicate that the core subunits interact with each other without 
their transmembrane regions.  
 
3.2.7 The heterotrimer of the soluble domains of GPI-T has catalytic activity  
With a method in hand to purify the three core subunits of GPI-T as a 
single complex, we were uniquely positioned to begin to characterize this 
complex in vitro for the first time. The foremost goal in our mind was to determine 
whether or not this truncated soluble complex retained catalytic activity. Such a 
discovery would dramatically improve the ability of researches, including us to 
characterize GPI-T. 
Our lab has developed a reliable FRET assay that would not only will help 
to analyze GPI-T activity as a whole complex, but could also facilitate analysis of 
single subunit contributions to GPI-T activity.216 This assay relies on synthetic 
peptides modified with a fluorophore (Abz, 2-aminobenzoic acid) and a quencher 
(Y*, nitrotyrosine) flanking the ω site amino acid. Our main substrate for this 
assay is based on the human campath-1 antigen, or CD52 (Figure 3.8), the 
smallest known substrate for GPI-T. After cleavage of its N-terminal ER signal 
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Figure 3.8: Transamidation reaction takes place in CD52. (a) Transamidation 
reaction. Red color amino acid indicates the fluorophore (Abz or 2-aminobenzoic 
acid) and the yellow color amino acid indicates the quencher (3-nitrotyrosine), 
which are flanking the ω-site serine shown in pale purple color. The right hand 
side contains the two products obtained from the transamidase reaction when 
incubated with GPI-T and hydroxylamine (NH2OH). First product is the 
hydroxamate that contain the fluorophore and the second product is the part 
contains the quencher. (b) Chemical structures of the fluorophore (Abz) and the 
quencher (3-nitrotyrosine). 
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sequence, CD52 is only 37 amino acids long.217,218,219 We synthesized this 
peptide with the addition of the fluorophore (red) and the quencher (yellow) on 
either side of the ω-site (pale purple). 
 When this peptide is incubated with purified GPI-T from yeast with a GPI 
anchor mimic such as hydroxylamine,220 the peptide is cleaved at the ω-site 
amide, which results in increase Abz fluorescence over time. Previous 
experiments carried out to develop this assay were conducted by Dr. Sandamali 
Ekanayaka (see Appendix A for more in vitro assay details).216 Dr Ekanayaka 
demonstrated that this peptide is a substrate for GPI-T and that GPI-T activity is 
dependant on hydroxylamine as a replacement for the full-length GPI anchor 
(Figure 3.9 (a). 
CD52 was used as the basis for the design and synthesis of two additional 
peptides, peptides 2 and 8 (Table 3.1). Several modifications were introduced 
into this peptide (shown in bold letters for both peptides, Table 3.1) to avoid any 
N-linked glycosylations221 or any oxidations222 (when using the crude lysates) to 
make the peptide substrate less complicated. Including these modifications, 
peptide 2 was synthesized with an 2-aminobenzoic acid (Abz) group on the N-
terminus amino acid and the 3-nitrotyrosine group on the 17th amino acid from 
the N-terminus (Table 3.1). Peptide 8 was similar to that of peptide 2 without its 
hydrophobic signal sequence. 
Using the same protocol developed by Dr. Sandamali Ekanayaka, we 
tested the soluble domains of the core subunits for GPI-T activity (Figure 3.9).216  
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Table 3.1: Peptide substrates to test GPI-T activity. The peptide substrates 
used in this chapter were built from the sequence of CD52. Changes are 
highlighted in bold. A 2-aminobenzoic acid (Abz) group was introduced at the N-
terminus and a 3-nitrotyrosine (Y*) was inserted in place of Ile17. Peptide 8 is 
similar to peptide 2 however it lacks the hydrophobic region of the C-terminal 
GPI-T signal sequence. 
	  
Peptide N –
terminus
N-terminal 
sequence
ω
site
Signal sequence C-
terminus
WT-CD52 H2N GQNDTSETSSP S ASSNISGGIFLFFVANAIIHLFCFS COOH
Peptide 02 Abz GQKDTSEKSSP S ASKNY*SGGIFLFFVAVAIIHLFHFS COOH
Peptide 08 Abz GQKDTSEKSSP S ASKNY*SGGIFL COOH
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Figure 3.9: The soluble domains of the core subunits show nucleophile 
independent activity. (a) Fluorescence measurements from an in vitro GPI-T 
assay conducted with the peptide 2 for the full length GPI-T in the presence (red) 
and absence (blue) of 10 mM hydroxylamine. (b) Fluorescence measurements 
from an in vitro GPI-T assay conducted with the peptide 2 for the soluble 
domains of the core GPI-T subunits in the presence (red) and absence (blue) of 
10 mM hydroxylamine. Full length GPI-T shows an NH2OH dependence where 
as soluble domains of the core GPI-T subunits show an reduction of NH2OH 
dependence. 
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Surprisingly, when incubated with peptide 2, a time-dependent increase in 
fluorescence was observed but this rate was independent of hydroxylamine; this 
result is in contrast to assays with full-length GPI-T, in which measurable activity 
was only obtained in the presence of hydroxylamine (Figure 3.9). However, as 
observed with wild-type GPI-T, our assay of the solubilized heterotrimer with the 
truncated peptide 8 revealed a much slower rate (data not shown). These 
preliminary data suggests that the pure soluble hetrotrimer retains some catalytic 
activity, however this activity is nucleophile-independent. The most likely 
explanation for this activity is that truncation of GPI-T has disrupted the active 
site of Gpi8 in a way that is sufficient to convert this enzyme’s normal 
transamidation activity into proteolytic activity. However, additional experiments 
are need to confirm this scenario.  
To better understand these results and to further explore the activity of this 
heterotrimeric complex, a carboxyfluorescein (CF) labeled CD52 is being 
synthesized. This peptide will be assayed as a substrate for our miniaturized, 
soluble GPI-T and any product produced by GPI-T will be characterized by LC-
MS to confirm that either transamidation or hydrolysis has occurred at the ω site. 
 
3.3 Discussion  
 We designed and overexpressed soluble domains for each of the three 
core subunits of GPI-T to facilitate experiments to examine the structure and 
organization of this enzyme. Here we’ve demonstrated that each pair of subunits 
can be isolated by immunoprecipitation or by purification, even in the absence of 
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the third subunit or any transmembrane domains. We were also able to co-purify 
these three soluble domains together in a heterotrimetric complex using only the 
TAP tag appended onto the C-terminus of Gaa150-343. Preliminary assays 
suggest that this solubilized complex has retained some GPI-T-like catalytic 
activity however this activity is nucleophile-independent (unlike full-length, wild-
type GPI-T, which requires a nucleophile). 
 In yeast, the full lengths forms of the core subunits Gpi8, Gpi16 and Gaa1 
purify as one complex.18 But the complexity of this complex and the low levels of 
purified protein obtained have hindered efforts to further characterize this 
enzyme. Here we were able to confirm interactions between the soluble domains 
of the core subunits, which will simplify additional analyses. These results 
represent just the beginning of a new era for understanding about GPI-T. Using 
these interactions, we can now determine the oligomerization states of these 
different complexes and, eventually, characterize the different contributions of 
each subunit towards GPI-T activity, providing insight into this complicated 
enzyme complex that had previously been inaccessible. 
 
3.4 Materials and methods 
3.4.1 Buffers and solutions 
Minimal medium (4X Sc-ura): 26.8 g Yeast nitrogen base, 6.4 g dropout 
mix, 0.4 g each adenine, leucine, tryptophan and histidine in 1L of water and 
sterile filtered before use. Minimal medium (4X Sc-trp): 26.8 g Yeast nitrogen 
base, 6.4 g dropout mix, 0.4 g each adenine, leucine, uracil and histidine in 1L of 
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water and sterile filtered before use. Minimal medium (4X Sc-ura-trp): 26.8 g 
Yeast nitrogen base, 6.4 g dropout mix, 0.4 g each adenine, leucine and histidine 
in 1L of water and sterile filtered before use. Lysis buffer: 50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, pH 7.2. Wash buffer: 50 mM NaH2PO4, 1 M NaCl, 
50 mM imidazole, pH 7.2. Imidazole elution buffer: 50 mM NaH2PO4, 300 mM 
NaCl, 300 mM imidazole, pH 7.2. Phosphate buffered saline (PBS) buffer: 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, 1 mM CaCl2, 0.5 mM 
MgCl2, pH 7.2.  Radioimmunoprecipitation assay (RIPA) buffer: 50 mM Tris-HCl, 
150 mM NaCl, 0.25 % w/v deoxycholate, 1 % igepal, 1 mM 
(Ethylenediaminetetraacetic acid) EDTA, pH 7.4. Calmodulin binding buffer: 10 
mM Tris-HCl, 150 mM NaCl, 1 mM Mg-acetate, 1 mM	  β-mercaptoethanol (BME), 
2 mM CaCl2, pH 8.0. Ethyleneglycoltetraacetic acid (EGTA) elution buffer: 5 mM 
Tris-HCl, 10 mM EGTA, 5 mM EDTA, pH 8.0.  FRET assay buffer: 50 mM Tris-
HCl, 0.1 M NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM MnCl2, 1 mM dithiothreitol 
(DTT), 1 mM phenylmethylsulfonylfluoride (PMSF), and 20 mM reduced 
glutathione (GSH), pH 7.4. 
 
3.4.2 Co-purification of the Gpi823-306-V5-His6:Gaa150-343-HA complex using 
Ni-NTA affinity purification 
Plasmids were constructed using Gateway cloning technology as 
described in section 3.2.1, by Dr Yug Varma and Ms Megan Ehrenwerth. Each 
gene was amplified using primers with appended AttB sites along with their 
native or CPY N-terminal signal sequences. PCR products were transferred into 
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the pDONR221 donor vector using standard E. coli transformation protocols and 
DH5α competent cells. After sequencing of each construct, genes were 
transferred into the appropriate destination vectors using the LR recombination 
mix (Invirtogen). Gpi81-306 was inserted into pYES-DEST52 (Invitrogen) and CPY-
Gaa150-343 into pAG414-GAL (Addgene). Both destination plasmids were 
transformed individually or together into InvSc1 competent cells using standard 
lithium acetate transformation (Invitrogen, pYES-DEST52 Gateway vector 
manual).  
A 50 mL overnight culture of Gpi81-306-V5-His6:CYP-Gaa150-343-HA or each 
single subunit was grown overnight and then transferred into a 1 L cell culture of 
the appropriate minimal medium (Sc-ura for Gpi81-306-V5-His6, Sc-trp for CYP-
Gaa150-343-HA and Sc-ura-trp for Gpi81-306-V5-His6:CYP-Gaa150-343-HA. 
Ultimately, cells from a 4 L culture were used for the each experiment. The 
cultures were grown in the minimal medium either lacking uracil or tryptophan or 
both, depending on the selection markers present in the plasmids used. 
Galactose (1%) was added to each large culture (overnight cultures were grown 
in 1% glucose) and each culture was grown for 12 hours prior to harvesting of the 
cells by centrifugation (3000 rpm for 5 min). Lysis buffer was added to the 
harvested cell pellet from a single 4 L cell culture, along with a quarter of a 
protease cocktail inhibitor tablet (Roche). An equal volume of glass beads (10 
mL) was added to the cell suspension, which was subsequently treated by 
vortexing for 30 sec followed by 30 sec on ice for 8 cycles. The cell lysate was 
centrifuged at 14,000 rpm for one hour using a JA20 rotor (Beckman Coulter). 
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The cleared supernatant was used for protein purification by Ni-NTA affinity 
purification. A 1 mL HisTrap HP column (GE Healthcare) was used for each 
purification. The columns were pre-equlibriated by washing each with 10 column 
volumes of lysis buffer. Each lysate was passed through a column at a rate of 0.5 
mL/min. Then the columns were washed with 5 column volumes lysis buffer 
followed by 50 column volumes wash buffer and another 5 column volumes lysis 
buffer. Proteins were eluted with 4 mL imidazole elution buffer and the eluent 
was concentrated using a 30,000 MW cutoff (Millipore) to a final volume of ~ 150 
µL.  
Western blots of SDS-PAGE gels were run to confirm the presence of the 
protein using the same protocol described in the materials and methods section 
of the Chapter 2. Gpi823-306 was visualized using an anti-V5 primary antibody 
(Sigma-Aldrich) and Gaa150-343 was visualized using an anti-HA primary antibody 
(Sigma-Aldrich). 
  
3.4.3 Co-immunoprecipitation using an HA tag (To evaluate Gpi823-306-V5-
His6: Gaa150-343-HA and Gpi823-306-V5-His6:Gpi1620-551-HA complexes) 
Cell lysate from a 100 mL cell culture was used for immunoprecipitation 
assays. Cells were overexpressed as described above, with appropriate 
adjustments to the media and volumes. Each cell pellet was resuspended in 1 
mL PBS buffer with the addition of a quarter tablet of a Roche protease cocktail 
inhibitor. The cells were broken with glass beads as described above (section 
3.4.2) and the cell lysate was obtained. An Anti-HA antibody (20 µg from a 1 
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mg/mL solution, Sigma Aldrich) was added and the solution was incubated 
overnight on a wheel at 4 ºC. A 20 µL sample of protein A agarose resin (Sigma-
Aldrich) was used for the immunoprecipitation studies. The resin was pelleted at 
12,000 rpm for 1 min and washed three times with 1 mL RIPA buffer. The resin 
was pelleted in between each wash before adding to the lysate/antibody mixture. 
The lysate/antibody/resin mixture was incubated with the resin at 4 ºC for 2 
hours. The beads were pelleted by centrifugation at 12,000 rpm for 1 min. The 
beads were washed four times with 1 mL RIPA buffer each time and one time 
with PBS buffer. The beads were pelleted again and then resuspended in 25 µL 
2X SDS gel loading dye. This suspension was boiled for 5 min and analyzed 
using SDS PAGE gels followed by Western blots as described in Chapter 2, 
section 2.4.3. Gpi823-306 was visualized using an anti-V5 primary antibody 
(Sigma-Aldrich) and Gaa150-343 and Gpi1620-551 were visualized using an anti-HA 
primary antibody (Sigma-Aldrich).  
 
3.4.4 TAP tag purification to isolate heterotrimer 
Cells were grown in Sc-ura-trp-leu minimal medium with galactose 
induction, essentially as described above. The cells were harvested at 3000 rpm 
for 5 min and were lysed using calmodulin binding buffer with the addition of a 
quarter tablet of a Roche protease cocktail inhibitor. Cell lysate from a 4 L cell 
culture was used for each purification. A 100 µL bed volume of calmodulin 
sepharose beads (Sigma-Aldrich), which had been pre-equilibriated by washing 
with 20 mL calmodulin binding buffer, was added to a column (Bio-Rad) at 4 ºC. 
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The cell lysate was added onto these beads and the slurry was incubated for 2 
hours at 4 °C on a rotating wheel. The beads were then washed with 30 mL ice-
cold calmodulin binding buffer at 4 °C. The proteins were eluted with 4 mL EGTA 
elution buffer and were concentrated using a 30,000 MW cutoff to a final volume 
of ~150 µL. The eluted proteins were analyzed using SDS-PAGE gels followed 
by Western blot analysis as described in the materials and methods in chapter 2. 
Gpi823-306 was visualized using an anti-V5 primary antibody (Sigma-Aldrich), 
Gpi1620-551 was visualized using an anti-HA primary antibody (Sigma-Aldrich), 
and Gaa150-343 was visualized using an anti-TAP primary antibody (Sigma-
Aldrich).  
 
3.4.5 FRET assay for the soluble domains 
 The FRET assay was carried out essentially using the protocol described 
in Dr. Sandamali Ekanayaka’s thesis.216 A 20 µL aliquot of a 1 mM peptide 
solution (dissolved in DMSO, either peptide 2 or 8) was added to 1.93 mL of 
FRET assay buffer. A Cary Eclipse spectrofluorimeter set to the following 
parameters: 321 nm excitation wavelength, 417 nm emission wavelength, 10 nm 
excitation slit width, 5 nm emission slit width. Each assay was conducted at 30 
ºC. The assays were initiated by adding 50 µL of the soluble GPI-T heterotrimer 
enzyme and fluorescence emission was monitored over time.  
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CHAPTER 4 
EFFECT OF GPI-T CORE SUBUNIT OVEREXPRESSION ON 
TRANSAMIDASE ACTIVITY IN VIVO 
 
4.1 Introduction 
The overexpression of different GPI-T subunits and the upregulation of 
certain GPI anchored proteins (e.g. urokinase plasminogen activated receptor; 
(uPAR),133 mesothelin, folate receptor alpha, and testisin) in various cancers 
make GPI-T a target for chemotherapies.103, 126 In 2008, the Trink group reported 
a profile of the expression patterns for the human GPI-T subunits, PIG-K (Gpi8), 
GPAA1 (Gaa1), PIG-S (Gpi17), PIG-T (Gpi16), PIG-U (Gab1) (with their 
corresponding yeast names in parenthesis) in 19 different cancers.110,187 All five 
subunits of GPI-T appear to play a role in different types of cancer 
propagation.223 However, the catalytic subunit, Gpi8, is the only subunit that is 
frequently downregulated in certain cancers. In this chapter, we describe the use 
of an in vivo assay in yeast to assess the contribution of each GPI-T subunit 
towards GPI transamidase activity.66 This approach is allowing us to develop 
yeast as a cancer model system to understand how changes in GPI-T subunit 
expression levels impact the presentation of GPI-anchored proteins on the cell 
surface.224-230  
We used an in vivo invertase assay that had been previously developed in 
our lab,66 to quantify changes in cell surface expression of GPI-anchored 
invertase in cell lines that were overexpressing Gpi8, Gpi16, or Gaa1. Different 
levels of GPI-T activity were observed based on the subunit that was 
overexpressed and the identity of the C-terminal signal sequence appended onto 
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invertase. Three signal sequences were examined based on the yeast yapsin 2 
protease (Y21), the campath-1 antigen (CA25) and UPAR (UP30). When Gpi8 
was overexpressed. 
 
4.2 Results 
4.2.1 Invertase assay development 
  Invertase is commonly used as a reporter assay because it hydrolyzes 
sucrose to fructose and glucose and the glucose produced can be measured 
using an enzyme coupled colorimetric assay.231  
Dr. Rachel Morrisette (an alumna of our lab) previously developed three 
Invertase variants that carry different C-terminal GPI-T signal sequences on 
them, each with a flag tag for immunoblotting (Figure 4.1 (a)).66 The signal 
sequences we used were from the following proteins: S. cerevisiae Yapsin 2 
protease (Y21), human campath-1 antigen (CA25) and human urokinase-type 
plasminogen-activated receptor (UP30). The plasmids coding these variants 
were transformed into an invertase knockout strain (SUC2-).66,209 In wild-type 
strains, endogenous invertase is highly secreted as a soluble cytoplasmic protein 
in yeast. When invertase is fused with GPI signal sequences and expressed in 
the SUC2- strain, GPI anchored invertase is translocated to the outer surface of 
the yeast cell membrane (Figure 4.2). The amount of cell surface invertase can 
be measured using a standard glucose assay.231 Importantly, this assay is  
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Sc Invertase
FLAG
GPI-­‐T	  signal	  seq.
INV: None
Y21: AωGGHNLNPPFFARFITAIFHHI
CA25: AωASSNISGGIFLFFVANAIIHLFCFS
UP30: AωAAPQPGPAHLSLTITLLMTARLWGGTLLWT
(a)
(b)
suc2- strain with
invertase construct 
suc2- strain with
invertase and each GPI-T 
constructs  
 
Figure 4.1: Invertase variants were constructed with three different GPI-T 
signal sequences. (a) Arrangement of invertase variants used herein. Top 
panel: cartoon representation of each construct. S. cerevisiae invertase was 
modified with a FLAG tag followed by different C-terminal GPI-T signal 
sequences. Bottom: the sequences used were from the S. cerevisiae Yapsin 2 
protease (Y21), the human campath-1 antigen (CA25) and human UPAR (UP30). 
(b) The SUC2- strain was transformed with an invertase construct (right) and a 
plasmid coding for overexpression of one GPI-T subunit (left). 
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Figure 4.2: GPI anchored invertase localized to the outer cell membrane 
through its GPI anchor. (a) Invertase constructed without GPI signal sequence 
secreted out in yeast cells. When the cells were washed Invertase can be 
removed from the cells. (b) GPI anchored Invertase is localized in the cell 
membrane. When washed, Invertase that are not attached with the GPI anchor 
washed away leaving GPI anchored Invertase onto the cell membrane. 
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conducted on live cells simply by adding sucrose and then measuring glucose 
production.  
 
4.2.2 The effect of endogenous expression of GPI-T on transamidase 
activity. 
We first recapitulated our previous results using this assay and 
endogenous levels of each GPI-T subunit.66,209 The Y21 C-terminal signal 
sequence yielded the highest levels of GPI-anchored invertase on the surface of 
cells. The activity of the UP30 and CA25 GPI-T signal sequences were 
normalized to that of Y21 (Figure 4.3). As we’ve previously reported, the two 
human GPI-T signal sequences (UP30 and CA25) are less effective as substrates 
for GPI-T. These results suggest species specificity, with yeast GPI-T favoring C-
terminal signal sequences from yeast proteins over those from human proteins. 
However, this dataset is too small to draw such a conclusion with any certainty. 
 
4.2.3 Effect of Gpi81-441 overexpression on GPI-T activity 
 The full-length Gpi81-414 gene was amplified by PCR with AttB sites 
included within the primers (Appendix C, Table C.1). The product was 
incorporated into the destination vector pAG414-GAL-Trp using Gateway cloning 
technology. This plasmid appended an HA tag onto the C-terminus of Gpi8 that 
was useful for immunoblotting purposes. This plasmid was transformed into the 
three SUC2- strains that were carrying the different invertase variants. Gpi8 was 
overexpressed by the induction of galactose for 12 hours and the harvested cells  
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Figure 4.3: Y21 shows highest GPI-T activity when GPI-T is expressed in 
endogenous levels.  Bar graph representing the GPI-T activity at endogenous 
levels of GPI-T expression. Y21 shows the highest GPI-T activity. UP30 and 
CA25 are normalized to that of Y21. Both CA25 and UP30 are weaker substrates 
for GPI-T. Raw data are shown in the Appendix C, Figure C.8. 
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were assayed immediately for invertase on their cell surface (see materials and 
methods).  
 Overexpression of Gpi81-414 showed some interesting results (Figure 4.4).  
The amount of invertase presented on the extracellular plasma membrane was 
quantified for each of our three signal sequences under endogenous levels (no 
overexpression) and then under conditions where Gpi8 was overexpressed. 
Results were normalized against the endogenous levels for each signal 
sequence in Figure 4.4 (a) and only against the Y21 levels in Figure 4.4 (b). 
Overexpression of Gpi8 had no effect on invertase activity with the constructs 
containing either the Y21 or the UP30 GPI-T signal sequence. In contrast, 
overexpression of Gpi8 doubled the amount of GPI anchored invertase when the 
CA25 GPI-T signal sequence was used. Without Gpi8 overexpression, the CA25 
signal sequence was the poorest of the three tested herein. With Gpi8 
overexpression, the amount of GPI anchored invertase produced with the CA25 
signal sequence rose to levels equivalent to those observed with the UP30 signal 
sequence. 
We designed our original invertase construct so that, once modified, the 
GPI anchored invertase would be the same no matter what signal sequence was 
used. Consequently, the amount of invertase presented on the cell surface is 
directly correlated to the ability of GPI-T to recognize and process each signal 
sequence as a substrate. We had not anticipated the possibility overexpression 
of one subunit would show signal sequence dependent changes on GPI-T 
activity. Nevertheless, the results in Figure 4.4 clearly show overexpression of  
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Figure 4.4: Overexpression of Gpi8 causes an increase in GPI anchoring of 
invertase with the CA25 signal sequence specifically. (a) GPI-T anchoring of 
invertase normalized to basal level expression levels for each signal sequence. 
(b) GPI-T anchoring of invertase normalized specifically to Y21 basal levels. Raw 
data are shown in the Appendix C, Figure C.9. 
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Gpi8 specifically enhances GPI-T activity when the CA25 signal sequence is 
present. These results suggest that Gpi8 recognizes at least part of the C-
terminal signal sequence, a scenario that has not previously been considered to 
our knowledge. 
 
4.2.4 The effect of Gpi161-610 overexpression on GPI-T activity. 
As described above for Gpi8, the full length Gpi16 subunit of GPI-T was 
also overexpressed and the impact of this overexpression was assessed by 
measuring changes in the amount of GPI anchored invertase present on the cell 
surface (Figure 4.5). Compared to cells expressing endogenous levels of the GPI-
T subunits, the overexpression of Gpi16 diminished the amount of GPI anchored 
invertase presented on the cell surface with all three GPI-T signal sequences. 
Invertase levels dropped by about 30% when the Y21 signal sequence was used 
and by about 60% when either the UP30 or the CA25 signal sequence was used. 
The role of Gpi16 in GPI-T is not known although it has been proposed 
that this subunit enhances the stability of the complex.232 Here we demonstrate 
that excess Gpi16 diminishes the catalytic competence of GPI-T, perhaps 
contradicting this stability hypothesis. In Chapter 3 of this dissertation, we showed 
that the soluble domain of Gpi16 forms stable dimeric complexes with Gpi8 and 
with Gaa1. Presumably excess Gpi16 leads to saturation of these dimeric 
complexes (e.g. all Gpi8 is bound to Gpi16) leaving extra Gpi16 to either bind to 
Gaa1 and prevent trimer complex formation or to interact with other proteins in 
the cell, disrupting normal cell function. The latter scenario is not unprecedented.  
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Figure 4.5: Gpi16 overexpression reduces the cell surface expression of 
GPI anchored invertase. (a) GPI-T anchoring of invertase normalized to basal 
level expression levels for each signal sequence. (b) GPI-T anchoring of 
invertase normalized specifically to Y21 basal levels. Raw data are shown in the 
Appendix C, Figure C.10. 
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 In humans, Gpi16 is known to activate several different signal transduction 
pathways (see Figure 1.9). 
 
4.2.5 Effect of Gaa11-614 overexpression on GPI-T activity. 
 Similar to Gpi16, Gaa1 overexpression leads to reduced activity overall In 
this case, the impact of individual signal sequences was more varied (Figure 4.6). 
A reduction of approximately 45% was observed with the Y21 signal sequence, 
65% with the UP30 signal sequence, and 80% with the CA25 signal sequence. 
Similar arguments as those proposed for the impact of Gpi16 overexpression can 
be made for Gaa1 as well. 
 
4.3 Discussion  
Using the invertase assay developed in our lab, we were able to 
quantitatively examine the impact of overexpression of the three core GPI-T 
subunits on GPI anchoring in vivo. Overexpression of each full-length GPI-T 
subunit caused altered levels of GPI anchored invertase that were dependent on 
the C-terminal GPI-T signal sequence presented in each construct. The data 
presented in Figures 4.4 – 4.6 can be further analyzed in a number of different 
ways. Figure 4.7 shows a comparison of these data organized by overexpressed 
subunit and Figure 4.8 shows these same data rearranged by signal sequence so 
that the impact of each subunit on a specific signal sequence can be easily 
observed.  
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Figure 4.6: Gaa1 overexpression reduces the cell surface expression of GPI 
anchored invertase.  (a) GPI-T anchoring of invertase normalized to basal level 
expression levels for each signal sequence. (b) GPI-T anchoring of invertase 
normalized specifically to Y21 basal levels. Raw data are shown in the Appendix 
C, Figure C.11. 
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Figure 4.7: Comparison of overall GPI-T activity on single subunit 
overexpression. GPI-T activity was measured for basal, Gpi8, Gpi16 and Gaa1 
expression. Y21 shows the highest activity on all Invertase variants. UP30 and 
CA25 have lower activity compared to Y21. Color coded bars represent each 
subunit overexpression.  
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The Y21 signal sequence always led to the highest levels of GPI anchored 
invertase. Overexpression of Gpi8 and Gpi16 had only nominal effects on GPI 
anchoring of invertase with either the Y21 or UP30 signal sequences (compared 
to endogenous levels with these signal sequences). In contrast, overexpression 
of Gaa1 caused a notable reduction in the amount of GPI anchored invertase 
presented on the cell surface. 
Like the Y21 signal sequence, overexpression of Gpi8 had little effect on 
the amount of GPI anchored invertase present on the cell surface when the UP30 
signal sequence was used. In contrast, this signal sequence was sensitive to 
overexpression of both Gpi16 and Gaa1, upon which the extent of GPI anchoring 
of invertase was diminished. 
Finally, the CA25 signal sequence was sensitive to overexpression of all 
three GPI-T subunits. Unexpectedly, Gpi8 overexpression doubled the efficacy of 
this weak signal sequence; however overexpression of either Gpi16 or Gaa1 
reduced anchoring of invertase with this signal sequence. 
Overexpression of GPI-T subunits occurs to varying extents in different 
types of cancers and between patients. The only subunit that is ever 
underexpressed in cancer is Gpi8, the catalytic subunit of GPI-T. Here we show 
the first correlations between subunit overexpression and GPI-T activity. It is 
possible that subunit overepression can lead to tumorigenesis by altering signal 
transduction pathways.  
The connection between subunit overexpression and increases in tumor 
growth could arise from one of three mechanisms. First, overexpression of a 
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single could lead to efficient complex assembly, thereby increasing the overall 
activity of GPI-T. Alternatively, subunit overexpression could actually decrease 
GPI-T complex assembly by oversaturating dimeric subunit intermediates. 
Finally, overexpression could lead to GPI-T subunits that are no in complexes 
with their normal protein partners and are therefore free to participate in other 
signal transduction pathways (e.g. uPAR in JAKS/STAT pathway).187 Our results 
with Gpi16 and Gaa1 clearly favor one of the latter two scenarios because we 
see a drop in GPI-T activity. Future efforts will be directed towards examining the 
distribution of these overexpressed subunits in vivo to determine whether or not 
they are completely free of GPI-T or in complexes with specific GPI-T subunits. 
 
4.4 Materials and methods 
4.4.1 Plasmid construction 
Each GPI-T plasmid was constructed similarly using Gateway cloning 
technology. Each gene was amplified using gene specific primers flanking attB 
overhangs. (These primers are listed in Appendix C, Table C.1) Each gene 
product was inserted into the pDONR221 vector (Invitrogen) following the 
manufacturer’s instructions. The resulting donor vector was used to transfer the 
genes into then with the destination vector, pAG414-Trp-GAL (Addgene) 
according to Invitrogen’s protocol for an LR reaction. The inserts were 
sequenced prior to use. Each was transformed into our SUC2- cell line using 
standard LiAc transformation protocols (Invitrogen, pYES-DEST52 Gateway 
vector manual).  
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4.4.2 In vivo Invertase assay 
For each assay, 5 mL cell cultures were used. Cells were grown at 30 ºC 
with 1% fructose (for SUC2- cells only with invertase plasmids), or with both 1% 
fructose and 1% galactose (for SUC2- cells with both the invertase plasmid and a 
plasmid for subunit overexpression) in Sc-Ura or Sc-Ura-Trp media, respectively. 
Cultures were grown for 12 hours and then immediately assayed. The OD600 was 
measured for each cell culture, and a volume equivalent to 1.0 absorbance unit 
was used for each assay. Cells were washed three times with pre-chilled 
autoclaved water. To the cells 40 µL of a 1 M NaOAc (pH 4.9) solution was 
added and was diluted to 400 µL with autoclaved water. This solution was 
incubated at 30 ºC for 30 min. A separate 0.5 M sucrose (in 1 M NaOAc, pH 4.9) 
sample was also incubated at 30 ºC prior to use. Next, sucrose (100 µL, 0.5 M 
solution) was added to each cell suspension. Time points (50 µL each) were 
removed at 1, 2, 3, 4, 5, 8, 11 and 16 min and quenched immediately into 75 µL 
of 0.2 M K2HPO4 (pH 10.0) followed by boiling for 3 min. The amount of glucose 
present in each time point was measures as previously described. 66,209    
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
GPI membrane anchoring of proteins is an important post-translational 
modification for eukaryotes. This process and the enzyme that is responsible for 
this modification, GPI-T, are poorly understood, particularly relative to their roles 
in human cancer. GPI-T contains 5 known subunits: Gpi8, Gpi16, Gaa1, Gab1 
and Gpi17. Even after 20 years of study, our understanding of the structure and 
function of these subunits remain in its infancy. Therefore, in this dissertation, we 
set out to look at the structure, stoichiometry, and contributions of these three 
core subunits towards GPI-T activity to better understand this enzyme. 
Chapters 2, 3 and Appendix B describe our efforts to structurally 
characterize the soluble domains of the three core GPI-T subunits (Gpi823-306, 
Gpi1620-551 and Gaa150-343). These three subunits were chosen for study herein 
because they are found in all eukarya (Gab1 and Gpi17 are missing in 
trypanosomes)74 and they can be isolated as a complex from S. cerevisiae. We 
focused our studies on the soluble domains of these subunits in order to simplify 
their purification and overexpression.  
There is precedent for working with soluble domains in isolation and this 
strategy is a common method for characterizing complicated membrane-
associated proteins.233,234,235 For example, the toll/interleukin-1 receptor (TIR) is a 
membrane protein that resides on the plasma membrane and plays an important 
role in inflammation and innate immune response. The crystal structure obtained 
from the soluble domain of the TIR10 receptor demonstrated that this receptor 
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assembles into a dimer, providing important insight into the function the full-
length, membrane-associated protein.236  
We evaluated the soluble domains of these core subunits to understand 
how they interact with each other and to reconstitute an active, soluble enzyme 
for future studies. This approach is powerful because it reduces the complexity of 
GPI-T. In addition, in trypanosomes, the catalytic subunit of GPI-T, Gpi8, is 
naturally a soluble protein without a TM domain, offering an interesting precedent 
for our approach.81 However, we were mindful of the fact that removing the TM 
domains from each subunit could change their behavior in vitro in terms of 
oligomerization or activity.  
The catalytic subunit, Gpi8, shares weak sequence similarity to caspase-
1. Caspases are catalytically active as simple homodimers or as homodimers in 
complex with specific activating proteins.20 Analogously, Gpi823-306 assembles 
into a mixture of homodimer and monomer (Chapter 2). These results suggested 
that the transmembrane domain of Gpi8 and/or other subunits are necessary for 
complete dimerization. This monomer/dimer Gpi823-306 mixture binds to peptide 
substrate but is catalytically inert, leading us to further hypothesize that either 
complete dimerization or the presence of one or more additional subunits is 
necessary for activity.83 Consistently, our characterization of the trimeric 
assembly of Gpi823-306, Gaa150-343 and Gpi1620-551 shows that is has proteolytic 
activity, demonstrating that the addition of Gaa1 and/or Gpi16 is sufficient to 
activate Gpi8, even in the absence of the native TM domains.  
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Also the results obtained from analyses of Gpi823-306 variants with 
mutations at N256 offer the first evidence that N23 might be glycosylated, even 
though it lies next to the N-terminal signal sequence. Moreover, elimination of N-
linked glycosylation at N256 (via either mutagenesis or the Endo H treatment) 
had little effect on the oligomerization state of Gpi8 indicating that N-linked 
glycosylation is not critical for Gpi8 dimerization.  
With Gpi823-306 as a homodimer, it is logical to hypothesize that the 
heterotrimer, containing all three core subunits, would also dimerize (to a dimer 
of the heterotrimer, in other words a heterohexamer) (Figure 5.1). In fact, the 
preliminary results presented in Appendix B are most consistent with the 
conclusion that the Gpi823-306:Gaa150-343 heterodimer is a dimer of dimers (a 
heterotrimer) offering additional support for this hypothesis. Thus, work in this 
dissertation argues that the three core subunits of GPI-T assemble into a dimer 
of trimers.  
Data from Chapter 3 show that each pair of subunits assembles into 
heterodimeric complexes, offering the first direct evidence that all subunits are in 
contact with each other. Furthermore, all three subunits assemble into a 
heterotrimer that can be purified by tandem affinity purification. Using a FRET 
assay previously developed in our lab,216 we have shown that the soluble 
heterotrimer (presumably containing two copies each of Gpi823-306, Gpi1620-551 
and Gaa150-343) is catalytically active but, surprisingly, its activity is not dependant 
on hydroxylamine. The most likely explanation for this activity is that truncation of 
GPI-T has disrupted the active site of Gpi8 in a way that is sufficient to convert 
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Figure 5.1: The expected stoichiometry for each of the complexes studied 
in this dissertation. The stoichiometry was predicted based on the observations 
that Gpi823-306 assembles as a mixture of monomer and homodimer and that 
Gpi823-306:Gaa150-343 is likely to exist as a dimer of dimers (heterotetramer).  
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this enzyme’s normal transamidation activity into proteolytic activity. In fact, full-
length GPI-T also has proteolytic activity.92  
In the future, we would like to further characterize the stoichiometry of 
each subunit pair and of the heterotrimer as these experiments will allow us to 
map, at least partially, the 3D organization of GPI-T. Our lab will use SEC, native 
PAGE and mass spectrometry to examine these soluble subunit mixtures for the 
presence of heterotetramer and heterohexamer. We also hope to use covalent 
crosslinking coupled to mass spectrometry to map the interfaces between each 
subunit. This type of crosslinking approach, coupled to our Rosetta models for 
each subunit, will paint a picture of GPI-T’s structure in the absence of any 
crystallographic information. As we increase our understanding of the structure of 
this enzyme, our ultimate goal will be to obtain a crystal structure of these three 
soluble domains in a complex. 
It will also be important to use our FRET assay, peptide binding and 
crosslinking experiments to evaluate each subunit’s contributions to GPI-T 
activity. The FRET assay developed in our lab will be used to determine which 
subunits are necessary for a functional GPI-T enzyme. Each subunit pair will be 
used to test for GPI-T activity, as we have reported for the heterotrimer in 
Chapter 3. The cleaved peptides product(s) will be analyzed using mass 
spectrometry to confirm that peptide cleavage occurred at the ω-site. Currently 
only the function of Gpi8 is known: this subunit contains the catalytic active site. 
And alone, the soluble domain of Gpi8 is inactive.83 To understand which subunit 
is responsible for the recognition of the C-terminal signal sequence, our lab will 
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use peptides that contain a photoactivated crosslinker (e.g. benzoylphenylalanine 
or p-azidophenylalanine) and a tag for co-immunoprecipitation studies. The 
peptide will be incubated with the heterotrimer, and irradiated with UV light to 
induce crosslinking. The subunits that interact with the peptide can be 
immunoprecipitated using the tag on the peptide (e.g. a biotinylated residue) and 
analyzed using western blots. The different bands corresponding to each subunit 
will be excised and analyzed using mass spectrometry after treating with trypsin.  
Chapter 4 and Appendix A of this dissertation describe the use of in vivo 
and in vitro assays developed in our lab to functionally characterize GPI-T. As in 
Appendix A, a FRET assay was used to examine GPI-T activity in vitro. This 
assay is the first reliable in vitro, quantitative assay developed for GPI-T.216 
Unfortunately we are still struggling to confirm the formation of the correct 
hydroxamate, indicating cleavage and modification at the ω-site residue, due to 
complications from the buffer system, such as the presence of digitonin. Once we 
confirm the in vitro assay, our lab will use small GPI anchor mimics that were 
synthesized by Dr. Franklin John,29 a former member from our lab, as GPI 
anchor mimics to test activity. These GPI anchor mimics have structures that are 
more similar to the GPI anchor and are likely to be better substrates than 
hydroxylamine. Ultimately, our lab will use this assay to examine the impact of 
subunit overexpression on GPI-T activity, as an in vitro model for cancer.  
Our lab has also developed an in vivo assay using invertase as a reporter 
enzyme.66 In chapter 4, this assay was used to assess the impact of 
overexpression of each core subunit on GPI-T activity. Our data show two 
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unexpected results; first, that activity increases for Gpi8 overexpression 
specifically for the signal sequence based on the CD52 protein substrate; and 
secondly, GPI-T activity went down upon overexpression of either Gpi16 or Gaa1 
independent of the signal sequence tested. These observations have led us to 
consider two possible mechanisms for subunit overexpression that could explain 
the connections between GPI-T and cancer (Figure 5.2): 1) catalytic subunit 
(Gpi8) overexpression is sequence dependent and increases GPI anchoring of 
some substrates that will specifically perturb signal transduction pathways; and 
2) overexpression of Gpi16 and Gaa1 apparently leads to disruption of the GPI-T 
complex, possibly freeing one or more subunits to activate signaling cascades. In 
both cases, perturbations of signal transduction pathways would lead to tumor 
initiation and propagation. In the future, overexpression of the Gpi17 and Gab1 
subunits will also be examined.  
This in vivo assay needs to be expanded to include a broader array of 
GPI-T signal sequences. Our lab will use more GPI-T signal sequences from 
humans (e.g. Glypican 1, Prostatin, Cripto 1 etc.) and yeast (e.g. Yapsin 2, 
Phospholipase PLB1 etc.) to better understand how the nature of the substrate 
signal sequence and subunit overexpression are connected. Ultimately, it is 
important to establish this assay in human cells to more directly examine the 
relationship between subunit overexpression and cancer. 
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Figure 5.2: Possible mechanism for signal transduction perturbations 
based on our results. The overexpression of Gpi8, the catalytic subunit 
increases the cell presentation of some GPI anchored proteins that can 
perturbate signaling pathways (top). The overexpression of Gpi16 and Gaa1 
reduces the cell presentation of GPI anchored proteins by reducing GPI-T 
activity. This bottom pathway might be due to the oversaturation of some subunit 
interactions leading to excess subunits participating in signal transduction. These 
pathways remain poorly understood. 
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The work in this dissertation takes an important step forward, providing 
new insights into GPI-T and new tools to better characterize this complicated and 
important enzyme.  We are only looking at the tip of the iceberg; there is 
significant more work to be done. 
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APPENDIX A 
GPI-T IN VITRO ASSAY PRODUCT CHARACTERIZATION 
 
A.1 Introduction 
The complexity of GPI-T has hindered a reliable quantitative assay that 
would allow researchers to analyze the kinetics of the protein. Even though there 
are many in vivo and in vitro experiments being developed to characterize GPI-T, 
the majority of them remain qualitative.81,215,96,55 Placental alkaline phosphatase 
(preproPLAP) and its miniature version, preprominiPLAP have been used over 
the last few decades in this capacity.55,54,56,237,238 The only in vitro quantitative 
assay reported to date is a fluorescence assay that uses a tetrapeptide 
containing the ω-3 to ω residues of a GPI-T substrate with an 
aminomethylcoumarin attached to the C-terminus of the ω amino acid.81 Several 
limitations were evident in this assay that included long incubation times and the 
absence of the C-terminal signal sequences for GPI-T in the synthetic, 
tetrapeptide substrate. There is a significant need for better assays with more 
comprehensive substrates to completely understand the behavior of GPI-T.  
Our lab has been developing a reliable assay base on fluorescence 
resonance energy transfer (FRET) that we expect not only to help us analyze 
GPI-T, but also to assess the contributions of individual substrates on GPI-T 
activity.216 Here we describe the solid-phase synthesis of peptides that are based 
on a known substrate for GPI-T (CD52) and have been modified to contain a 
fluorophore  (2-aminobenzoic acid) and a quencher (nitrotyrosine) flanking the ω-
site amino acid (Figure 3.9, Chapter 3).216 CD52 is one of the shortest known 
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substrate for GPI-T: this protein is only 37 amino acids long with its C-terminal 
signal sequence and once the signal sequence is cleaved the protein is only 12 
amino acids in length.217,64,218 
When this peptide is incubated with purified GPI-T from yeast with a GPI 
anchor mimic like hydroxylamine,220 a time-dependent increase in fluorescence 
was observed. These experiments were conducted by Dr. Sandamali Ekanayaka 
(data not shown).216 This fluorescence response was consistent with 
transamidation by GPI-T. In this appendix, synthesis of two peptide substrates for 
this GPI-T assay will be described. These peptides were based on CD52 and on 
a yeast substrate for GPI-T called Yapsin 2. Our efforts to confirm that 
transamidation had occurred by isolating the hydroxamate peptide product from 
this assay will be described. This project is ongoing and is therefore provided as 
an appendix. 
 
A.2 Results 
A.2.1 Synthesis of peptide substrates using solid phase peptide synthesis 
A modified version of our CD52 substrate peptide was synthesized with a 
biotin tag added to the side chain of Lys3, the 3rd amino acid from the N-terminus 
(peptide 3). Compared to the peptide 2 (Chapter 3) that used to characterize 
GPI-T,216 the only modification done onto peptide 3 was the addition of the biotin 
tag. This biotin was inserted to facilitate the evaluation of peptide products from 
our assay. Additionally, several modifications were introduced into this peptide 
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compared to its native form to avoid N-linked glycosylations (when using crude 
yeast lysates)221 or complications that could arise from oxidations222 similar to 
peptide 2 (Chapter 3) (Table A.1).  
Yapsin 2 is a yeast aspartyl protease, and is a GPI-T substrate with a 
validated ω-site.239 Yeast Yapsin 2 also known as Aspartic proteinase MKC7 with 
596 aminoacids carrying a molecular weight of 64 kD. It has a N-terminal signal 
sequence (residues 1-22) that target the ER localization and a C-terminal signal 
sequence (residues 576-596) recognized and modified using GPI-T.75 We have 
chosen 21 amino acid long C-terminal signal sequence of Yapsin 2 to create 
peptide 11 with additional five amino acid residues towards the N-terminus. We 
introduced the Abz, fluorophore to the Lys4, the 4th amino acid from the N-
terminus and the 3-nitrotyrosine, quencher onto the 11th amino acid from the N-
terminus. We have positioned the fluorophore and the quencher more closely 
compared to CD52 to increase the sensitivity of the assay. Also, the N-terminus 
of this peptide was acetylated to inhibit any additional modifications that could 
take place (Table A.1). 
Both peptide substrates were synthesized by solid phase peptide 
synthesis using either a Prelude peptide synthesizer or by manual synthesis. 
Each substrate was cleaved from the resin, purified by HPLC and characterized 
by ESI-MS prior to applications to the study of GPI-T (See materials and 
methods). 
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Table A.1: The peptides synthesized compared with their native form. Red 
colored amino acids are the changes that’s being done compared to the wild type 
sequence. Peptide 3 is designed to represent CD52 and peptide 11 was 
designed to represent Yapsin 2.  
 
Peptide N-terminal sequence ω GPI-T signal sequence
CD52 GQNDTSETSSP S ASSNISGGIFLFFVANAIIHLFCFS
Peptide 3 Abz-GQK(biotin)DTSEKSSP S ASKNY*SGGIFLFFVANAIIHLFHFS
Yapsin 2 STRKE N GGHNLNPPFFARFITAIFHHI
Peptide 11 (Acetylated)STRK(Abz)E N GGHNY*NPPFFARFITAIFHHI
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A.2.2 Purification of GPI-T and in vitro assay for Yapsin2. 
Professor Andreas Conzelmann kindly provided us with yeast strain 
FBY656. In this strain, the wild-type gpi8 gene has been disrupted with a 
kanamycin cassette. Viability of the strain is supported by plasmid YCplac22, 
which contains a GST-tagged version of the gpi8 gene. The GST was inserted 
into the gene such that it is encoded immediately after the N-terminal ER 
localization sequence and before the beginning of the soluble domain of Gpi8 
such that the final expressed protein contains the GST sequence followed by 
Gpi823-441. GPI-T was purified by glutathione affinity purification according to the 
protocol of Fraering et al.216,18 Affinity purification of GST-Gpi81-411 was confirmed 
by SDS-PAGE and anti-GST blot, which visualized the presence of Gpi81-411-
GST (Figure A.1). Insufficient protein was obtained to confirm the co-purification 
of Gpi16 and Gaa1 (in contrast to the results of Fraering et. al.).18  
Dr. Ekanayaka’s assay development and optimization experiments were 
conducted using our synthetic CD52 peptide substrate (peptide 2). Because this 
peptide is based on a human substrate for GPI-T, we set out to develop a 
substrate based on the yapsin protease, a substrate for S. cerevisiae GPI-T. 
216,75 Our expectations were that this peptide would be a stronger substrate for 
GPI-T. Therefor, we carried out the in vitro assay with varying peptide 
concentrations of peptide 11 (Figure A.2 (a)). Data was normalized to peptide 2, 
representing CD52 (Figure A.2 (b)). The red line indicates the background 
fluorescence for the assay done without any enzyme. However, even at 5X the 
concentration of peptide 2 (the CD52 substrate), activity with our Yapsin 2  
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1 2
 
 
 
Figure A.1: Purification of GST-Gpi823-411.  An anti-GST blot to confirm the 
presence of GST-Gpi823-411. Lane 1: Molecular weight markers, Lane 2: Purified 
GST-Gpi823-411, this construct has a calculated molecular weight of 72 kD.  
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Figure A.2: The synthetic Yapsin 2 peptide is not a good substrate for yeast 
GPI-T. (a) Initial rates to compare the GPI-T activity on peptide 2 (CD52) and 
peptide 11 (Yapsin 2) peptide substrates with different concentrations.(b)The bar 
graph shows a comparison of the initial rates obtained from our assay using our 
synthetic peptide 2 and peptide 11 peptides. Our peptide11, did not show activity 
even at 5X higher concentrations than our typical CD52 assay. The red line 
indicates the background fluorescence, the assay conducted without GPI-T (No 
enzyme control). 
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peptide (peptide 11) was not observed (Figure A.2). (Figure courtesy of Dr. 
Sandamali Ekanayaka).216  
 
A.2.3 Analysis of the peptide products from our GPI-T assay 
We used peptide 3 (biotynilated version of CD52) (Table A.1) to facilitate 
characterization of the peptide products of our GPI-T assay. After an extended 
incubation of this peptide with purified GPI-T in the presence of hydroxylamine, 
streptavidin purification was carried out to purify all biotin tagged peptides. 
Different peptides were separated by high performance liquid chromatography 
(HPLC) and then analyzed by ESI-MS. The predicted ω-site of CD52 is Ser12. 
Therefore we expected to isolate a peptide containing the 12-N-terminal amino 
acids, with the C-terminal serine modified with hydroxylamine to the hydroxamate 
by GPI-T. This putative product has a calculated exact mass of 1610 g/mol. The 
calculated masses for this peptide as well as other possible biotynilated peptides 
are summarized in Table A.2. 
However, only masses that roughly matches to the hydroxamates of 4th , 
7th and 8th amino acids from the N-terminus were seen (807, 1124 and 1253 D). 
Also we were able to observe two prominent peaks that we initially resembles as 
the hydroxyl product of 8th amino acid (1250 D) and it’s hydroxamate product 
(1237 D) (Figure A.3). We were surprised to observe multiple cleavage sites and 
the predicted ω site was not cleaved. Further analysis of these products 
confirmed that the peaks corresponding to 8th amino acid are due to the 
presence of digitonin.  We used digitonin as a detergent, which will solubilize 
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Table A.2: The calculated molecular weights for hydroxamate and hydroxyl 
products. Red colored amino acids are the changes that’s being done compared 
to the wild type sequence. Molecular weights for both hydroxyl and hydroxamate 
products were calculated for assuming cleavage takes place on the 4th, 7th, 8th or 
on the 12th amino acid from the N-terminus. All the MW are in g/mol. 
 
Peptide 
product
Sequence Calculated MW of 
the hydroamate
product
Calculated MW
of the hydroxyl 
product
12 mer Abz-GQK(biotin)DTSEKSSPS 1611 1624
8 mer Abz-GQK(biotin)DTSEK 1237 1250
7 mer Abz-GQK(biotin)DTSE 1124 1137
4 mer Abz-GQK(biotin)D 807 820
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- Hydroxylamine 
+ Hydroxylamine 
162 kDa 162 kDa
16 kDa
D D
D
 
 
Figure A.3: Mass spectra of assay product analysis. Two mass spectra are 
shown which were acquired from assays conducted in the presence (top) and 
absence (bottom) of hydroxylamine. 
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GPI-T, the transmembrane protein complex. Digitonin is a glycoside with a 
molecular weight of 1229 g/mol. When digitonin is present in a sample, mass 
spectrum gives a well-known240,241 pattern with a difference of 162 g/mol between 
peaks (Figure A.3). This difference corresponds to the loss of one glucose 
molecule. 
Next, we introduced a water:chloroform:MgCl2 extraction step into our 
assay workup (see materials and methods) to more completely extract the 
digitonin from our samples prior to analysis. After extraction, both the aqueous 
and organic layers were analyzed in a peptide gel (Figure A.4) and by thin layer 
chromatography (Figure A.5) to verify that peptides partitioned into the aqueous 
layer with the digitonin in the organic layer. In this case, we used our biotinylated 
peptide (see Table A.1) so that partitioning could be visualized by Western blot 
after separation in a 20% tris-tricine peptide gel (Figure A.4). As hoped, the 
peptide was separated into the aqueous layer. A comparison of lanes 1 and 3 in 
Figure A.4 reveals the presence of a shorter peptide in lane 1 that is not present 
in lane 4. While it is clear that cleavage of the parent peptide was poor and 
incomplete, this smaller peptide may represent the cleavage product from our 
assay. In fact, this biotinylated CD52 peptide appears to be a poor substrate for 
GPI-T, as judged by the low fluorescence increase observed over time in our 
standard assay.  
Thin layer chromatography in hexane:ethylacetate with a carbohydrate 
specific stain was used to check for the presence of digitonin in the aqueous and 
organic layers after extraction. Digitonin and mannitol were tested as controls as  
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Anti-biotin blot
No nu With nu No E
W W WC C C
1 2 3 4 5 6 7
*
**
 
 
Figure A.4: Analysis of extraction step  to separate our peptide substrate 
from digitonin. A 20% tris-tricine peptide gel was run to analyze the aqueous 
(lanes 1, 3, and 5) and organic (lanes 2, 4, and 6) layers from this extraction. The 
samples in lanes 1 and 2 are from an assay conducted with hydroxylamine; 
Lanes 3 and 4 are from an assay in the absence of hydroxylamine. Lanes 5 and 
6 are from a mock assay without GPI-T. Lane 7 contains the biotinylated CD52 
peptide as a positive control. *Indicates the band that corresponds to our CD52 
substrate. **Indicates a new band that may represent the product peptide from 
our assay.	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1 – Digitonin
2 – No enzyme (C)
3 – No enzyme (W) 
4 – With nuc (C)
5 – With nuc (W)
6 – No nuc (C)
7 – No nuc (W)
8 – Mannitol 
1    2     3    4    5    6    7   8 
Digitonin
 
 
Figure A.5: Digitonin can be removed from assay samples by organic 
extraction. Peptide samples were separated from digitonin by 
water:chloroform:MgCl2 extraction and the organic and aqueous layers were 
analyzed by thin layer chromatographic separation. Lanes 2,  4,  and 6, represent 
the aqueous layers  from these extractions; lanes 3, 5, and 7 represent the 
corresponding organic layers. Lane 1 shows digitonin without extraction. Lanes 2 
and 3 are from a mock assay conducted without  enzyme. Lanes 4 and 5 are 
from an assay conducted with hydroxylamine. Lanes 6 and 7 are from an assay 
conducted in the absence of hydroxylamine. 
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both were used in our buffers. Using this method we confirmed that digitonin is 
extracted into the chloroform layer, suggesting that peptides in the aqueous layer 
are more suitable for analysis by ESI-MS. Efforts are underway to optimize this 
method to purify the assay products obtained with peptide 2 (without the biotin 
tag), followed by LC-MS to characterize the products. 
 
A.3 Discussion 
 The importance of GPI-T in human cancer has created an urgent need for 
a reliable quantitative assay for this enzyme. A FRET assay was first developed 
in our lab using crude microsomes and then with pure GPI-T.216,209 This assay 
relies on hydroxylamine as a GPI anchor mimic and reduced activity was seen in 
the absence of hydroxylamine, confirming the nucleophilic dependence of this 
assay.216 
Even using the yeast GPI-T, activity was reduced when a peptide based 
on yeast Yapsin 2 was used as a substrate, compared to our human CD52 
substrate. However, the Yapsin 2	  peptide substrate was synthesized with only 
three amino acids downstream of the ω-site. It is possible that this truncation 
explains the poor substrate behavior of this peptide. A peptide containing a 
longer N-terminal sequence is currently being synthesized for testing as a 
substrate.  
The last step required for the development of our GPI-T assay is to 
confirm that transamidation has occurred by demonstrating the formation of a 
hydroxamate product. Complications arose due to the presence of digitonin in our 
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assay buffer and the biotin tag added on to our CD52 peptide substrate. We have 
now developed an extraction protocol to remove the digitonin from our assay. 
Efforts to characterize these peptide products are ongoing. 
	  
A.4 Materials and methods 
A.4.1 Buffers and solutions 
HBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate, DIPEA: N,N-diisopropylethylamine, NMP: N-methyl-2-
pyrrolidone, cleavage solution: 1.35 mL of Trifluoro Acetic acid (TFA), 50 uL of 
Anisole and 95 uL of Thioanisole. Anisaldehyde stain for TLC: 9.2 mL 
anisaldehyde, 3.75 mL Acetic acid, 338 mL 95% Ethanol, 12.5 mL concentrated 
sulfuric acid.  
Peptide gel (20%) preparation: 
Gel buffer (3X, pH 8.5), 3 M Tris base, 1 M HCl, and 0.3 % SDS. Separating 
layer, 15 mL 39:1 Acrylamide/Bis acrylamide, 10 mL of 3X gel buffer, 2.4 mL of 
glycerol, 2.5 mL of water, 100 uL of  Ammonium peroxodisulfate (APS), 10 uL of 
Tetramethylethylenediamine (TEMED).  
Stacking layer, 1 mL of 39:1 Acrylamide/Bis acrylamide, 3 mL of 3X gel buffer, 8 
mL of water, 90 uL of APS, 10 uL of TEMED.  
2X gel loading dye, 2 mL of Tris HCl pH 6.8, 2 mL of 10% Sodium dodecyl 
sulfate (SDS), 4 mL of glycerol, 1.8 mL of water and 5 uL of β-mercaptoethanol 
(BME).  
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10X Cathode buffer at pH 8.25, 1 M Tris base, 1 M Tricine, and 1% SDS. 10X 
Anode buffer, 1 M Tris base, 0.225 M HCl.  
 
A.4.2 Solid phase peptide synthesis 
All the peptides were synthesized manually or on a Prelude peptide 
synthesizer (Proteins technology). Pre-substituted Fmoc-Ile-Wang resin (for 
Yapsin 2 peptides, 100-200 mesh, 0.6 mmol/g) or Fmoc-Ser(tBu)-Wang resin (for 
CD52, with a 100-200 mesh, 0.6 mmol/g) were used. All the amino acids were 
coupled from 200 mM stock solutions with 400 mM HBTU and 200 mM DIPEA 
using NMP as the solvent. The peptides were either doubly coupled as needed. 
Manual coupling was performed after testing each amino acid coupling and 
deprotection using standard nynhydrin test. Deprotection was achieved with 20% 
piperidine in NMP for 20 min to remove the Fmoc group protecting group from 
each N-terminal amino acid. The peptides were cleaved from the resin using 
peptide cleavage solution, with mixing at room temperature for two hours. Cold 
ether was used to precipitate the cleaved peptide. The precipitate was then 
lyophilized from water. Each sample was purified by reverse phase HPLC 
(Beckman coulter) using a C3 column and ACN: water as the solvent system with 
1% TFA. The identity of each peptide confirmed by ESI-MS in collaboration with 
the Trimpin Lab).    
 
A.4.3 Purification and assay of GPI-T 
The growth, purification and the in vitro assay of GPI-T was conducted 
according to the protocols developed by Dr. Sandamali Ekanayaka.216 The 
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concentrated proteins were then analyzed using 10% SDS PAGE gel followed by 
Western blot. The presence of GST-Gpi8 was visualized by Western blot as 
described in the materials and methods of chapter 2. 
 
A.4.4 In vitro assay product analysis for the biotynilated peptide. 
After the biotinylated CD52 peptide was incubated with GPI-T under our 
standard assay conditions with NH2OH for six hours, the resultant mixture was 
loaded onto streptavidin resin (1 mL bed volume) after washing, biotinylated 
peptides were eluted with hot.216 The resultant eluent was lyophilized and 
analyzed by MAIV, a mass spectroscopic method developed in Dr Trimpin’s lab 
and was ran by Dr. Ellen Inutan using 3-Nitrobenzonitrile (3-NBN) as the 
matrix.242 
 
A.4.5 Assay product separation using water:chloroform separation  
Two milliliter assay samples were used for the extractions. A 3:2:1 ratio of 
chloroform:methanol:MgCl2 (4 mM) was added to each assay to become 6 mL 
total volumn. Each sample was vortexed for two minutes and then let it to stand 
until the layers are settled. The chloroform layer was separated and collected into 
a new tube and a second extraction was carried out for the water layer. Both the 
water and chloroform layers were separately collected, dried or lyophilized and 
frozen until further characterization.  
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A.4.6 Peptide gel for product analysis  
Samples from the extractions described in the previous section were 
analyzed for peptide content using a 20% peptide gel followed by a Western blot 
using anti-biotin to detect the biotin tag on our peptide. A 20% separating layer 
and a 4% stacking layer were used to prepare the gels (see above). Samples 
were loaded onto the gels with 2X gel loading dye (after heat denaturation) and 
each gel was ran at 100 V for two hours. The peptide gel was transferred onto 
PVDF membrane using similar protocols as in chapter 2 and visualized using 
anti-biotin (1 mg/mL, Sigma-Aldrich) followed by secondary anti-mouse 
antibodies. 
 
A.4.7 Thin layer chromatographic analysis 
TLC was performed with hexane:ethylacetate 50:50 solvent system. The 
solvent chamber was saturated first before running the TLC. After elution, the 
plate was dried and stained with anisaldehyde to visualize digitonin. To this end, 
the TLC plate was sprayed with the stain and then it was heated gently until 
spots were visible. Different sugars light up in different colors. A control spot with 
pure digitonin was included as a positive control. 
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APPENDIX B 
STRUCTURAL CHARACTERIZATION OF YEAST GPI823-306:GAA150-343 
SOLUBLE DOMAINS IN E. COLI 
 
B.1 Introduction 
From the five known subunits of GPI-T, Gpi8, Gpi16 and Gaa1 co-purify 
as a core-heterotrimer in yeast,18 we consider these three subunits the “core” 
components of GPI-T. Even though each subunit is known to be essential for 
transamidase activity, the exact contribution of each subunit to activity is 
unknown in terms of structure, connectivity, stoichiometry and function.12,19,5, 232 
An initial characterization of the soluble domain of the catalytic subunit, Gpi823-
306, revealed that it is inactive due either to the absence of one or more of the 
other subunits or a requirement for soluble domain II and its TM domain. 
Nevertheless, this subunit does bind peptide substrates.83 Therefore, as the next 
step, efforts have been initiated to characterize the structural and functional 
involvement of the other two core subunits, Gpi16 and Gaa1 (see Chapter 3) . 
This appendix describes our efforts towards the structural characterization of 
yeast Gpi823-306:Gaa150-343 overexpressed and purified from E. coli.  
Gaa1 has a single, large soluble domain with six transmembrane 
helices.75 Sequence alignments and the three dimensional structural predictions 
by us and others Show an evolutionary connection between Gaa1 and a metal-
dependant aminopeptidase.185,186 However, when grown in E. coli, 
overexpression of Gaa150-343 is toxic.207 To overcome this problem, we 
examined the impact of co-expression of Gaa150-343 with GST-Gpi823-306 in E. 
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coli. Our hypothesis was that complex formation between these two subunits 
would alleviate the toxicity of Gaa1 overexpression. This appendix explains our 
efforts towards optimizing growth to maximized the yields of both subunits 
(Gpi823-306 and Gaa150-343 and to determine the stoichiometry of this complex. 
 
B.2 Results 
B.2.1 Overexpression and purification of Gpi823-306:Gaa150-343 
The plasmid pJLM017 (Gaa150-343) was transformed into BL21(DE3)RIL 
Codon Plus cells (Stratagene); this plasmid adds a His6 tag onto the N-terminus 
of Gaa150-343. Since Gaa150-343 alone is toxic to E. coli, GST-Gpi823-306 (pJLM008) 
was co-transformed into this strain in an effort to alleviate toxicity.207 Co-
expression was conducted at low temperature. The protein complex was purified 
using glutathione affinity purification, which will purify GST-Gpi823-306 along with 
Gaa150-343. The purified proteins were analyzed using an anti-GST Western blot, 
anti-His blots and Coomassie-stained gels (Figure B.1). Further, these purified 
proteins were analyzed using size exclusion chromatography (SEC) and native 
PAGE. 
 
B.2.2 Analysis of Gpi823-306:Gaa150-343 complex by SEC. 
       Native PAGE gels were used to analyze the complex formation between 
Gpi823-306 and Gaa150-343; however, they were unsuccessful (data not shown). 
Next we injected the purified putative protein complex onto an SEC column.  
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Anti-GST blot Anti-His blot Coomassie gel
(a) (b) (c)1 2 1 2 1 2
 
 
Figure B.1: Glutathione sepharose purification of GST-Gpi823-306 results in 
the co-purification of His6-Gaa150-343. GST-Gpi823-306 and His6-Gaa150-343 were 
simultaneously overexpressed in BL21(DE3)RIL codon plus cells the GST tag on 
GST-Gpi823-306 was used to purify both proteins. (a) Anti-GST Western blot (b) 
Anti-His6 blot. (c) Coomassie stained gel. In all three panels, lane 1 molecular 
weight markers, Lane 2: purified protein.  
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(Figure B.2). Since the amount of protein were not enough to analyze using 
native PAGE, the SEC spectra of the complex was overlaid with the SEC 
molecular weight marker (Figure B.2 (a)). 
Fractions were collected, concentrated and analyzed using SDS-PAGE gels 
followed by Western blot visualization using anti-GST and anti-His6 antibodies  
SEC exclusion revealed three peaks (Figure B.2 (a)). The first peak 
(fractions 4-6) presumably represents aggregates. Western blot analysis 
demonstrated that these fractions did not contain either GST-Gpi823-306 or His6-
Gaa150-343. The second peak (fractions 7-9) was not baseline resolved and 
appeared as a shoulder to the first peak. This peak contained both GST-Gpi823-
306 or His6-Gaa150-343 (Figure B.2. (b)) and eluted with a molecular weight range of 
252-164, which is most consistent with the formation of an α2β2 complex, 
containing two copies of both GST-Gpi823-306(α) and His6-Gaa150-343 (β). The 
third peak eluted with a calculated MW range of 164-70 (fractions 9-10). These 
fractions predominantly contain GST-Gpi823-306 and are most consistent with a 
homodimer of this subunit. To further confirm the formation of an α2β2 
heterotetramer, we set out to optimize the yields of the Gpi823-306:Gaa150-343 
expression. 
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Figure B.2: SEC analysis of GST-Gpi823-306:His6-Gaa150-343 complex forms a 
heterotetramer. GST-Gpi823-306:His6-Gaa150-343 was overexpressed and purified 
using glutathione affinity purification. The purified protein was injected into the 
SEC column. (a) Spectrum of the complex overlaid with the SEC marker. Blue 
color is the spectrum of the complex. Black color id the spectrum of the molecular 
weight marker. The eluted fractions were concentrated and analyzed using 
western blots of anti-GST and anti-His blots. (b) Top panel: anti-GST western 
blot, bottom panel: anti-His western blot. For each lanes, lane 1: molecular 
weight marker, lane 2: the injected protein sample, lane 3-10: concentrated 
protein fractions collected from the SEC column. If GST-Gpi823-306 is α and His6-
Gaa150-343 is β, αβ~ 94 kD, α2β~ 153 kD and α2β2~ 188 kD. The protein complex 
was observed at a higher molecular weight greater than 150 kD indicates that the 
complex is the heterotetramer.   
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B.2.3 Impact of small molecule additives on protein expression and 
purification 
A number of different small molecules can be added to growth media and 
purification buffers to increase protein stability and solubility and to reduce 
aggregation of proteins.243 Several additives such as sugars, osmolytes, amino 
acids and their derivatives, detergents (non ionic, zwitter ionic and ionic), salts 
(mild and strong chaotropes and kosmotropes), alcohols, polyols and polymers 
have been used to increase protein stability.243,244,245,246,247 We tested a series of 
additives first to increase the solubility of GST-Gpi823-306 and to see the effect of 
the small molecules on GST-Gpi823-306 dimerization (Figures B.3 & B.4).  
GST-Gpi823-306 was first grown in small scale (25 mL) in the presence of 
different small molecules, (erythritol, mannitol, xylitol, trehalose, gly-gly, glycerol 
and proline) added to the growth media (see materials and methods). The final 
OD600 was measured and each culture was divided into two. One half was 
purified in the presence of the same additive and the second half was purified in 
the absence. The production of GST-Gpi823-306 was examined using Western 
blots with anti-GST antibodies (Figure B.3), native PAGE gels were also used to 
test the effect of each additive on protein solubility and protein dimerization 
(Figure B.4). However, little effects were observed in terms of protein stability 
and solubility for GST-Gpi823-306. 
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Control Erythritol Mannitol Xylitol
Trehalose Gly-Gly Glycerol Proline
(a) (b) (c) (d)
(e) (f) (g) (h)
Anti-GST blot Anti-GST blot Anti-GST blot Anti-GST blot
Anti-GST blot Anti-GST blot Anti-GST blot Anti-GST blot
1 2 31 2 1 2 3 1 2 3
1 2 3 1 2 3 1 2 3 1 2 3
 
 
Figure B.3: The impact of small molecules on the production and stability 
of GST-Gpi823-306. Small molecules were used to growth media and purification 
buffers in an effort to enhance the overproduction and solubility of GST-Gpi823-
306. (a) Control growth without any additional small molecules. (b)-(h) Growth 
media were supplemented with small molecules, as follows; (b) erythritol, (c) 
mannitol, (d) xylitol (e) trehalose (f) gly-gly (g) glycerol and (h) proline. In (a) lane 
1: molecular weight markers, and lane 2: affinity purified protein. For panels (b)-
(h), lane 1: molecular weight markers, lane 2: small molecule was added only to 
the growth medium, lane 3: small molecule was added to both the growth 
medium and to the lysis buffer used in the purification.  
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Erythritol Mannitol  Xylitol  Trehalose  Glycerol  Proline  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
GlyGly   
 
Figure B.4: Small molecules additives do not enhance dimerization of GST-
Gpi823-306. GST-Gpi823-306 purified from cultures containing different small 
molecule additives was loaded onto a native PAGE gel to analyze the amount of 
dimer formed. Lane 1: control protein without any small molecule additive, lanes 
2, 4, 6, 8, 10, 12, and 14: Each small molecule  was added only to the growth 
medium. Lanes 3, 5, 7, 9, 11, 13, and 15: Each small molecule was added to 
both the growth medium and the lysis buffer.  
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We also tested these small molecules on the overproduction of GST-
Gpi823-306: His6-Gaa150-343. Cultures were grown separately with each of the small 
molecule additives as described above for GST-Gpi823-306. Each cell pellet was 
purified with or without the same additive in the purification buffer using 
glutathione sepharose affinity purification. The presence of GST-Gpi823-306: His6-
Gaa150-343 were analyzed using anti-GST and anti-His Western blots, respectively 
(Figure B.5).  
Gaa150-343 was observed in protein samples, with erythritol added into both 
growth medium and to the purification, with trehalose added to the growth 
medium and purified even in the presence and absence of trehalose and with 
xylitol was added only into the growth medium. However, when trehalose was 
added onto the large growth medium (1 L), no protein was overexpressed 
indicating this protein complex should grown and purify in small scale cultures. 
 
B.2.4 Switching the tags to increase expression of Gaa150-343 
Since the overexpression of Gaa150-343 alone is toxic to the cells and we 
couldn’t grow the complex in larger cultures, we assumed by altering the tags it 
would help the overexpression of the complex. Therefore we switched tags in 
Gpi823-306 to His6 and Gaa150-343 to GST. The individual overexpression and 
purification of each protein yield a reasonable quantity of proteins. However, 
when both the proteins were expressed in same cell and purified using 
glutathione affinity purification, only GST-Gaa150-343 was purified and His6-Gpi823-
306 was washed during the washing step (Figure B.6). 
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Figure B.5: Effect of small molecules on overexpression and purification of 
GST-Gpi823-306:His6-Gaa150-343 Both GST-Gpi823-306 and His6-Gaa150-343 was 
overexpressed in BL1(DE3)RIL codon plus cells in the presence of small 
molecules. Glutathione affinity purified proteins in the presence or absence of 
small molecules were analyzed using western blots of anti-GST and anti-His. (a)-
(h) Top panel: anti-GST blot to visualize GST-Gpi823-306 and bottom panel: anti-
His blot to visualized His6-Gaa150-343. (a) Control sample without any sugar. Lane 
1: Molecular weight marker, Lane 2: purified protein (b)-(h) Overexpressed and 
purified samples with addition of sugar molecules. Lane 1: Molecular weight 
maker, Lane 2: Purified protein in the absence of small molecules, Lane 3: 
Proteins were purified in the presence of each small molecule. 
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Anti-His blot
Anti –GST blot
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Figure B.6: Glutathione affinity purified GST-Gaa150-343 complex didn’t co-
purify His6-Gpi823-306. Both His6-Gpi823-306 and GST-Gaa150-343 was 
overexpressed in BL1(DE3)RIL codon plus cells and purified using glutathione 
affinity purification. Top panel: Anti-His blot to indicate the presence of His6-
Gpi823-306, Bottom panel: Anti-GST blot to confirm the presence of GST-Gaa150-
343. For both the gels lane 1: molecular weight marker, lane 2: pellet, lane 3: 
lysate, lane 4: flow through, lane 5: wash 1, lane 6: wash 5, lane 7: eluted 
protein. Lane 5 of the anti-His blot indicate Gpi823-306 has washed and didn’t 
participate in forming the complex.  
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These results suggest that His6-Gpi823-306 is not binding to GST-Gaa150-343 may 
due to the GST-tag interfering with the Gpi823-306 and Gaa150-343 binding 
interface. 
 
B.3 Discussion 
 Even thought preliminary native PAGE and ESI-IMS-MS results indicate 
the presence of the heterotetramer of GST-Gpi823-306: His6-Gaa150-343, we wanted 
observe a robust tetramer of this complex. The toxicity of Gaa150-343 when grown 
in E.coli has hindered the isolation of the complex in a higher yield. Therefore we 
had to carry out optimization of the growth and purification of this protein complex 
to increase the yield. 
 Attempts were carried out to characterize GST-Gpi823-306: His6-Gaa150-343 
using SEC, but repetitions were unsuccessful. Therefore to increase the yield of 
the protein complex, small molecules were added to the growth medium. Even 
thought the addition of small molecules onto the growth medium, didn’t enhance 
the solubility and stability of the Gpi823-306-GST, in GST-Gpi823-306: His6-Gaa150-
343 a higher yield of the complex was obtained with erythritol, trehalose and xylitol 
in small growth cultures. When small molecules were used in larger cultures 
protein complex was not overexpressed leading us to think that may be amount 
of air and the cell crowding may effect on the protein’s expression. Therefore, 
growth should carryout in small scale, to obtain a higher yield of the protein and 
re-analyze for the heterotetramer should done using native PAGE and SEC. 
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B.4 Materials and methods 
B.4.1 Overexpression and purification of GST-Gpi823-306: His6-Gaa150-343 
Plasmids were constructed by Dr Y. Varma and Dr R. Morissette.207,209 
Overexpression and purifications were carried according to Dr. Varma’s 
protocols.207 The presence of proteins was confirmed by SDS-PAGE gels 
followed by Western blots. Anti-GST Western blots done similar to Chapter 2, 
materials and methods. Anti-His western blots were carried out with a 1 µg/mL 
concentrations of anti-His primary antibody from mouse (AnaSpec) followed by 
the secondary anti-mouse antibodies (Sigma-Aldrich) with a working 
concentration of 1 µg/mL. 
 
B.4.2 Use of small molecules in overexpression and purification of GST-
Gpi823-306 and GST-Gpi823-306: His6-Gaa150-343 complex 
Overnight pre-cultures were grown without any small molecules. A volume 
of 1 mL pre-culture was added to a 25 mL culture with appropriate antibiotics and 
1% glucose, along with small molecules to obtain the following final 
concentrations. erythritol: 0.5 M, mannitol: 0.5 M, xylitol: 1 M, trehalose: 0.75 M, 
gly-gly: 0.1 M and glycerol: 5%, proline, 0.5 M.243 Samples were grown at 19 oC 
until it reaches the OD600 to ~0.5. Once the desired OD600 was obtained, a final 
concentration of 1 mM IPTG was added and was induced for another two hours. 
The final OD600 was measured prior to the purification. The cell pellet was 
dissolved to obtain a similar concentration of cells and was purified following the 
same protocols for GST purifications as described in Dr Varma’s thesis.207  
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The purified cells were analyzed using SDS-PAGE gels and native PAGE 
gels where appropriate followed by anti-GST and anti His Western blots as 
described in materials and methods of Chapter 2. 
 
B.4.3 Switching tags to obtain His6-Gpi823-306: GST-Gaa150-343 complex 
Plasmids pJLM008 (GST-Gpi823-306) and pJLM017 (His6-Gaa150-343) was 
used to obtain the His6-Gpi823-306 and GST-Gaa150-343 plasmids. The restriction 
enzyme cleavage was done to get Gpi823-306 and Gaa150-343 gene products and 
was inserted into pCDF-1B and to pGEX-4T3 plasmids respectively to switch the 
tags.  
Glutathione sepharose affinity purification was used to purify the complex. 
The protocols for overexpression and purification of these proteins are similar to 
previous. 
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APPENDIX C 
EXPANDED FIGURES AND TABLES 
	  
1 2 3 4 5 6 7 8
	  
	  
Figure C.1: Extended gel pictures with respect to Figure 2.1. 
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Figure C.2: Extended gel pictures with respect to Figure 2.2. 
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Figure C.3: Extended gel pictures with respect to Figure 2.5. 
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Figure C.4: Extended gel pictures with respect to Figure 2.9. 
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Figure C.5: Extended gel pictures with respect to Figure 3.2.  
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Figure C.6: Extended gel pictures with respect to Figure 3.3.  
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Figure C.7: Extended gel pictures with respect to Figure 3.4.  
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Figure C.8: Extended gel pictures with respect to Figure 3.5.  
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Figure C.9: Extended gel pictures with respect to Figure 3.6. 
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Figure C.10: Extended gel pictures with respect to Figure 3.7. 
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Figure C.11: Raw data, for Figure 4.3.   
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Figure C.12: Raw data for Figure 4.4.  
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Figure C.13: Raw data for Figure 4.5.  
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Figure C.14: Raw data for Figure 4.6. 
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Glycosylphosphatidylinositol transamidase (GPI-T) is a complicated, 
membrane-bound, multi-subunit enzyme that catalyzes an essential post-
translational modification. This enzyme attaches GPI anchors to the C-termini of 
various proteins that contain a proper GPI-T signal sequence. Gpi8, Gaa1, 
Gpi16, Gpi17 and Gab1 are the five known subunits that may encompass the 
fungal GPI-T; Gpi8 is the catalytic subunit, but the functions of the other subunits 
remain essentially unknown. In humans, different GPI-T subunits are upregulated 
in different cancers, making GPI-T a target for cancer research. However, in spite 
of the importance of this enzyme, little is known about how it assembles into an 
active enzyme complex, the stoichiometry of this complex, or the roles of the 
different components. Here we use soluble domains of the three core subunits 
(Gpi8, Gpi16 and Gaa1) to investigate the stoichiometry of the enzyme as well as 
to study the functions of each subunit in vitro. Additionally, overexpression of the 
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full-length core subunits was used to study the enzyme’s behavior on 
transamidation in vivo.  
 Due to the complex nature of this protein and the fact that it is membrane 
associated, we set out to simply this enzyme into a more tractable system. In 
chapters 2 and 3 of this thesis, we focused on the soluble domains of the core 
subunits, Gpi81-306, Gaa150-343 and Gpi161-551. These soluble domains were 
overexpressed and their interactions and stoichiometry were characterized. Gpi8, 
the catalytic subunit, has weak sequence similarity to caspase-1 and assembles 
into a homodimer. Also, N-linked glycosylation of one asparagine in this subunit 
is not essential for dimerization. Co-immunoprecipitation of the soluble domains 
of Gpi81-306:Gaa150-343, Gpi81-306:Gpi161-551 and Gpi161-551:Gaa150-343 
demonstrated that these subunits interact with each other at least in 
heterodimeric complexes. Initial characterization of the Gpi823-306:Gaa150-343 
complex is consistent with the formation of an α2β2 heterotetramer.  Also, these 
three subunits Gpi81-306:Gaa150-343:Gpi161-551 can be co-purified as an intact 
complex.  Preliminary results show that this core heterotrimer has nucleophile-
independent activity. Our results will help to elucidate the function and resolve 
the complexity of GPI-T. Efforts are underway to determine the stoichiometry of 
each subunit and the contribution of each subunit towards transamidase activity.   
To better understand how changes in expression affect GPI-T activity, and 
as a model for this enzyme in cancer, we have developed an in vivo strategy to 
monitor and quantify the effect of subunit overexpression on cell surface 
presentation of GPI-anchored proteins in Saccharomyces cerevisiae. Here we 
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used Invertase as a reporter enzyme. Three GPI-T signal sequences were 
appended to the C-terminus of invertase and the amount of cell surfaced, GPI 
anchored invertase was measured. Overexpression of Gpi8, the catalytic subunit 
had little effect on GPI anchoring of invertase with two of these three signal 
sequences; however, the amount of cell surface invertase was nearly doubled 
when the weakest signal sequence was used. Compared to Gpi8, 
overexpression of either Gpi16 or Gaa1 downregulated GPI-T activity with all 
three signal sequences. To our knowledge, these results represent the first direct 
examination of the impact of subunit overexpression directly on GPI-T activity. 
Our results suggest that overexpression of a single GPI-T subunit either disrupts 
assembly of active GPI-T or frees these subunits to participate  different cellular 
functions. 
The results presented in this dissertation represent the beginning of a new 
era aimed at understanding GPI-T and provide new tools and approaches to 
achieve this important goal.	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